Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Document
Document related concepts
no text concepts found
Transcript
University of California San Francisco Updated: 5/29/2014 CURRICULUM VITAE Name: Laura J. van ‘t Veer Position: Professor, Department of Laboratory Medicine Angela and Shu Kai Chan Endowed Chair in Cancer Research School of Medicine University of California, San Francisco Address: N-415, 2340 Sutter St UCSF Box 0808 San Francisco, CA 94143-0808 Voice: (415) 476-2063 Fax: (415) 502-2773 Email: [email protected] http://cancer.ucsf.edu/people/vantveer_laura.php EDUCATION: 1976-80 University of Amsterdam, Amsterdam, Netherlands B.Sc. Biology, Molecular Oncology 1980-84 University of Amsterdam, Amsterdam, Netherlands M.Sc. Experimental Oncology 1984-89 University of Leiden, Leiden, Netherlands Ph.D. Medicine, Oncogene Activation and Tumorigenesis LICENSES, CERTIFICATION: 2002 Clinical Molecular Geneticist (Dutch Society Anthropogenetics) PRINCIPAL POSITIONS HELD: 1989-1991 Harvard Medical School and Massachusetts General Hospital, Boston Postdoctoral Fellow Cancer Center 1992-1993 The Netherlands Cancer Institute Postdoctoral Fellow Division Molecular Carcinogenesis 1993-2010 The Netherlands Cancer Institute Molecular Biologist Department of Pathology, Division of Experimental Therapy 1993-2010 The Netherlands Cancer Institute Group Leader Molecular Pathology Department of Pathology, Division of Experimental Therapy 1993-2005 The Netherlands Cancer Institute Head DNA Diagnostic Laboratories Molecular Pathology 1995-2005 The Netherlands Cancer Institute Head DNA-diagnostic Laboratory Family Cancer Clinic 1997-2003 The Netherlands Cancer Institute Head Family Cancer Clinic 2002-2010 Leiden University Medical Center, The Netherlands Honorary Staff Member 2004-2007 Agendia BV, Amsterdam Chief Operating Officer 2007-2013 Agendia BV, Amsterdam Chief Research Officer 2007-2010 The Netherlands Cancer Institute Clinical Division Head (ad interim) Page 1 of 38 Department of Surgery Division of Diagnostic Oncology: Clinical Departments Pathology, Radiology, Nuclear Laura J. van ‘t Veer – CV Medicine, Clinical Chemistry, Family Cancer Clinic 2008-2010 The Netherlands Cancer Institute Research Department Head Department of Experimental Therapy (includes Molecular Pathology) 2008-2010 University of California, San Francisco Visiting Associate Professor Cancer Center 2010-present University of California, San Francisco Professor 2011-present University of California, San Francisco Angela and Shu Kai Chan Endowed Chair in Cancer Research Department of Laboratory Medicine Department of Laboratory Medicine OTHER POSITIONS HELD CONCURRENTLY: 2010 University of California, San Francisco Visiting Associate Professor Department of Pathology 2010 University of California, San Francisco Visiting Associate Professor Department of Radiology 2010 University of California, San Francisco HS Clinical Instructor Department of Laboratory Medicine 2010-present University of California, San Francisco Associate Director Cancer Center 2010-present University of California, San Francisco Director Applied Genomics, Cancer Center 2010-present University of California, San Francisco Professor Department of Pathology 2010-present University of California, San Francisco Professor Department of Radiology 2011-present University of California, San Francisco Faculty Member Biomedical Sciences Graduate Program 2011-present University of California, San Francisco Faculty Member Pharmaceutical Sciences and Pharmacogenomics HONORS AND AWARDS 1989 – 1990 Long-term Fellowship, NWO The Netherlands Organization for Scientific Research, 's-Gravenhage, The Netherlands 1991 – 1994 Postdoctoral Fellowship, The Irvington Institute for Medical Research, New York, USA 2005 International Agency for Research on Cancer (IARC) Medal of Honor, Lyon, France 2006 Van der Scheuren award lecture for European Breast Cancer Research, EBCC5 2007 European Society Medical Oncology (ESMO) Lifetime Achievement Award for Translational Research in Breast Cancer 2007 – 2011 Breast Cancer Research Fund (BCRF-Pink Ribbon US) grant award 2009 First Annual Harry and Edith Gladstein Award, Indiana University, School of Medicine 2012 AACC Outstanding Speaker Award 2014 Second Prize, European Union Prize for Women Innovators KEYWORDS/AREAS OF INTEREST: Breast cancer, genetics, clinical trials, molecular diagnostics, applied genomics, precision medicine Page 2 of 38 Laura J. van ‘t Veer – CV PROFESSIONAL ACTIVITIES CLINICAL 1993-2010 The Netherlands Cancer Institute, Head Molecular Pathology, DNA diagnostics laboratory of Family Cancer Clinic, Family Cancer Clinic Hereditary Cancer, Chair Division of Diagnostic Oncology (2007-2010) 2011-present UCSF, Director CLIA certified laboratory Applied Genomics, CA 05D2034158 SUMMARY OF CLINICAL ACTIVITIES In 1993 Laura van ‘t Veer founded the Molecular Pathology Diagnostic Laboratory as part of the Clinical Pathology services of the hospital of The Netherlands Cancer Institute. She was head of this Laboratory until 2005, after which she became deputy Head until 2008. In 1995 she started the Family Cancer Clinic for genetic counselling and DNA diagnostics. She was Head of this Department until 2003, remained Head of its DNA diagnostics laboratory until 2005, after which she became deputy Head until 2008. The Molecular Pathology and the Family Cancer Clinic Diagnostics Laboratories acquired jointly ISO17025 Quality Accreditation in 2001, for which she served as Qualified Laboratory Director until 2005, and deputy Laboratory Director until 2008. In 2007 she became Chair (ad interim) of the Division of Diagnostic Oncology, which includes the Netherlands Cancer Institute Clinical Departments of Pathology, Radiology, Nuclear Medicine, Clinical Chemistry and the Family Cancer Clinic, and served in this position until March 2010. In 2003 Laura van ‘t Veer was co-founder of the Netherlands Cancer Institute spin–off Molecular Profiling Diagnostic Company Agendia, Amsterdam, The Netherlands, since 2008 also based in California US. As Chief Operating Officer from 2003-2007 she was responsible for the operations and served as Qualified Laboratory Director for the ISO17025 Quality Accreditation in 2004 as well as for the FDA 510K In vitro Diagnostic Multiple Index Assay (IVDMIA) clearance in 2007. Later Agendia’s laboratory also obtained CLIA certification and CAP accreditation both for the Netherlands and the US facilities. Since 2010 Dr. van 't Veer is Director Applied Genomics within the UCSF Helen Diller Family Comprehensive Cancer Center and obtained in 2011 CLIA certification for this laboratory to provide molecular testing for patient diagnostics, translational studies, and clinical trials. The Applied Genomics Laboratory also provides the UCSF Medical School/UCSF HDFC Cancer Center a testing and method validation resource under CLIA regulation for assay development and performance in clinical trials. The assays (including predictive algorithms) will be developed to fulfill FDA-IDE standards. This resource is used for the nationwide I-SPY 2 trial. PROFESSIONAL ORGANIZATIONS Memberships 1995-2010 Netherlands DNA Working Group Clinical Genetics 1995-present Netherlands Collaborative Group on Hereditary Breast Cancer (HEBON) 1996-present American Association for Cancer Research 2007-present International Cancer Genomics Consortium 2008-present ISPY2 TRIAL program (US) 2009-present European Molecular Biology Organization (EMBO) 2010-2011 New York Academy of Sciences 2011-present American Association of Cancer Research, Board of Directors 2014-present National Biomarker Development Alliance, Scientific Advisory Board Service to Professional Organizations Page 3 of 38 Laura J. van ‘t Veer – CV 1996-2002 Dutch Society of Pathology Molecular Pathology Steering committee 2000-2007 Dutch Cancer Society (KWF) Signalerings Commissie Kanker (Cancer Health Care and Cancer Research Platform) 2002-2003 Royal Netherlands Academy of Arts and Sciences (KNAW) Council for Medical Sciences, Gene Patenting Committee 2002-2004 The Netherlands Cancer Institute Scientific Advisory Council 2002-present European Organization for Research and Treatment Steering Committee Breast Group of Cancer (EORTC) 2002-2010 Ministries of Health, Education and Sciences (Raad voor Gezondheids Onderzoek) Advisory Council on Health Research 2004-2008 Netherlands Collaborative Group on Hereditary Breast Cancer (HEBON) Steering Committee Chair 2004-present EU 6th framework, Transbig Transbig/Mindact Biotechnology Committee Chair; Executive Committee 2006-2009 European Society of Medical Oncology (ESMO) Faculty Coordinator for Basic Cancer Research 2007-2010 Ministry of Health (Gezondheidsraad) Genetics Advisory Council 2008, 2009 American Society of Clinical Oncology (ASCO) Annual Meeting Faculty 2008, 2012 SABCS-AACR San Antonio Breast Cancer Symposium Annual Symposium Faculty 2008-2010 American Association of Cancer Research (AACR) AACR-FDA-NCI Biomarkers Collaborative 2009-present American Association of Cancer Research (AACR) Clinical and Translational Research Steering Committee 2009-present ISPY2 Trial program (US) 2010-2011 American Association of Cancer Research (AACR) Annual Meeting Program Committee 2011-2013 SABCS-AACR San Antonio Breast Cancer Symposium 2011-2014 American Association of Cancer Research (AACR) Board of Directors 2011-present American Association of Cancer Research (AACR) Task Force on Regulatory Science and Policy 2012-present Turning the Tide Against Cancer Through Sustained Medical Innovation 2012-present American Association of Cancer Research (AACR) Science Policy and Legislative Affairs Committee 2012-present National Biomarker Development Alliance (NBDA) Member Executive Committee; Co-Chair Biomarker Committee Symposium Planning Committee Advisory Committee SERVICE TO PROFESSIONAL PUBLICATIONS: 2010 Lancet Oncology International Advisory Board INVITED PRESENTATIONS INTERNATIONAL 2000 2000 2000 2001 Symposium Foundation Hereditary Tumors, Utrecht, The Netherlands ASCO, Special Symposium New Perspectives in Hereditary Breast Cancer, New Orleans, USA ESTRO 19, Teaching Course and Teaching Lecture Microarrays, Istanbul, Turkey ECCO 11, Special Lecture ‘Genomics’, Lisbon, Portugal Page 4 of 38 Laura J. van ‘t Veer – CV 2002 2002 2002 2002 2002 2002 2002 2002 2002 2003 2003 2003 2003 2003 2003 2003 2004 2004 2004 2004 2004 2004 2004 2004 2004 2005 2005 2005 2005 2005 2005 2005 2005 2005 2006 2006 2006 2006 2006 2006 2006 2006 2006 2006 2006 2007 2007 2007 2007 2007 2007 2007 2007 2007 2007 2007 2007 2007 Symposium Foundation Hereditary Tumors, Utrecht, The Netherlands 3rd European Breast Cancer Conference, Symposium Molecular Biology, Barcelona, Spain Oncogenomics 2002, AACR & Nature Genetics Conference, Dublin, Ireland ASCO, Special Symposium Microarray Profiling in Cancer, Orlando, USA Expertmeeting Deutsche Krebshilfe 2002, ‘After sequencing the human genome’, Bonn, Germany EMBL/EMBO Symposium Functional Genomics: The Future of Biology, Heidelberg, Germany Toxicogenomics International Forum 2002, Okazaki, Japan Deutsche/Oest Gesellshaft Hamatologie-Onkologie, Symposium Human Genome, Munich, Germany NCI/EORTC ‘From Discovery to Clinical Practice’, Washington, USA ChipstoHits, Boston, USA Oncogenomics 2003, AACR Conference, Phoenix, USA 14th Breast Cancer Linkage Consortium Meeting, Madrid, Spain National British Oncological Association Meeting, Manchester, England EU-US Workshop Molecular Signature of DNA Damage Induced Stress Responses, Cortona, Italy 9th ESACP Meeting, Amsterdam, The Netherlands Emerging perspectives in Clinical Cancer Research, Cape Town, South Africa Cancer Complexity 2004 Symposium, Institute Gustave Roussy, Paris, France CNIO Symposium Basic and Translational Cancer Research, Madrid, Spain 2nd Multidisciplinary ColoRectal Cancer Congress, Noordwijk, The Netherlands Soc. Toxicology, Symposium Molecular Profiling and Computer Modeling, Philadelphia, USA 4th European Breast Cancer Conf, Symposium Clinical Pharmacogenomics, Hamburg, Germany NCI/EORTC 3rd International Meeting on Cancer Molecular Markers, Brussels, Belgium ASCO, Special Symposium and Meet the Professor, New Orleans, USA Oncogenomics – State of the Art and Challenges, Montreal, Canada ESMO, Vienna, Austria EWOC, Flims, Switserland IARC 40th Anniversary Symposium, Lyon, France Milan Breast Cancer Conference, Milan, Italy Molecular Biology of Breast Cancer, Molde, Norway Oncogenomics 2005, San Diego, USA AACR Advances in Breast Cancer Research, La Jolla, USA ECCO 13, Paris, France Era of Hope, DOD, Philadelphia, USA General Motors Annual Scientific Cancer Symposium, Washington, USA Bio2006, EU directive, Chicago, USA NCI-EORTC Cancer Molecular Markers, Stone Mountain, USA ThinkTank16, Cayman Islands Gene to Cure Breast Cancer, Amsterdam, The Netherlands EBCC5, VanderScheuren Award lecture, Nice, France AACR Annual Meeting, Educational session and Public Forum, Washington DC, USA Milan Breast Cancer Conference, Milan, Italy Brecosm, Paris, France AACR Molecular Diagnostics in Cancer Therapeutic Development, Chicago, USA ESMO, Symposium Prognostication by gene profiling, Istanbul, Turkey ESTRO, Symposium Molecular Metastasis, Leipzig, Germany ThinkTank17, Cancun, Mexico Gordon Conference Molecular Diagnostics, Ventura Beach, USA AACR Oncogenomics 2007 (co-chair), Phoenix, USA AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics, San Francisco, USA Dutch Cancer Patient Day CGC-KWF-NFK (co-chair), Utrecht, The Netherlands ESO/EIO-lecture, Milan, Italy Australian Cancer Genomics Meeting, Couran Cove, Australia AACR 2nd Molecular Diagnostics in Cancer Therapeutic Development, Atlanta, USA Minimal Residual Disease, Hamburg, Germany Annual Italian Oncology Meeting AIOM, Palermo, Italy ‘Wetenschapscafe’ Rode Hoed, Amsterdam, The Netherlands MammaZone German Patient Advocates, Augsburg, Germany Advances in Hormone Positive Breast Cancer Symposium (Esteve), Barcelona, Spain Page 5 of 38 Laura J. van ‘t Veer – CV 2007 2008 2008 2008 2008 2008 2008 2008 2008 2009 2009 2009 2009 2009 2009 2009 2009 2009 2009 2009 2010 2010 2010 2010 2010 2010 2010 2010 2010 2011 2011 2011 2011 2011 2011 2011 2012 2012 2012 2012 2012 2012 2013 2013 2013 2013 2013 2013 2014 Belgian Society of Medical Oncology – Jules Bordet Oncology Meeting, Brussels, Belgium 6th European Colorectal Cancer Congres, Berlin, Germany AACR Annual Meeting, Educational Symposium and Scientific Symposium, San Diego, USA 5th European Breast Cancer Conference, Berlin, Germany AACR Translational Cancer Medicine 2008, Monterey, USA 3rd Int Conf Molecular Diagnostics in Cancer Therapeutic Development (co-chair), Atlanta, USA NCRI Cancer Conference, Birmingham, United Kingdom Association for Molecular Pathology, Dallas, USA 31st Annual San Antonio Breast Cancer Symposium, San Antonio, USA ThinkTank19, Herradura, Costa Rica AACR Annual Meeting, Meet-the-Expert and Career Development Forum, Denver, USA 3rd Intl Symp Cancer Metastasis and Lymphovascular System, San Francisco, USA ASCO Annual Meeting, Discussant Breast Cancer Stem Cells, Orlando, USA ECCO/ESMO, Triple Neg symposium and FFPE debate, Berlin, Germany ISOBM, Amsterdam, The Netherlands Juntendo University Tokyo, Japan Japanese NCCN Symposium, Tokyo, Japan Osaka Medical Center, Osaka, Japan AIS, Firenze, Italy 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, USA EUSOMA e-grandrounds, webseminar AACR Special Conference Translational Medicine, Amsterdam, Netherlands International Cancer Genomics Consortium Meeting, Madrid, Spain CHI Molecular Medicine TRI Conference, San Francisco, USA EBCC-7, Barcelona, Spain AACR Annual Meeting, Plenary Lecture, Washington, USA IMPAKT, Brussels, Belgium New York Academy of Science, Genomics in Cancer, Barcelona, Spain ESTRO, Symposium Local Recurrence, Barcelona, Spain AACR Annual Meeting, USA BIG-NABCG Annual Meeting, Chicago, USA COGS BCAC Stockholm, Sweden Milan Breast Cancer Symposium, Gene Expression Profiles, Italy AACR Translational Workshop, Boston, USA Advanced Breast Cancer (ABC) Meeting, Lisbon, Portugal 34th Annual San Antonio Breast Cancer Symposium, San Antonio, USA EBCC-8, Vienna, Austria AACR Annual Meeting, USA Personalized Cancer Care Symposium, Oslo The Princess Takamatsu Foundation Symposium, Tokyo, Japan Asian Breast Cancer Meeting, Tokyo, Japan 35th Annual San Antonio Breast Cancer Symposium, San Antonio, USA Peking Union Medical College Hospital, Annual Symposium: Translational Medicine, Beijing, China AACR Annual Meeting, USA ECCO-ESMO, Amsterdam, The Netherlands 2nd Advanced Breast Cancer (ABC2) Meeting, Lisbon, Portugal Personalized Prevention of Breast and Prostate Cancer, Stockholm, Sweden 36th Annual San Antonio Breast Cancer Symposium, San Antonio, USA AACR Annual Meeting, USA NATIONAL 2002 2004 2004 2005 2005 MIT-Cancer Center, Cancer Perspectives Symposium, Boston, USA Expedition Inspiration Fund for Breast Cancer Research, 8th Ann Meeting, Sun Valley, USA Breast SPORE, Chapel Hill, USA Toxicogenomics-Gordon Conf, New Hampshire, USA Chicago Lynn Sage Breast Cancer Meeting, USA Page 6 of 38 Laura J. van ‘t Veer – CV 2007 2008 2009 2009 2010 2011 2011 2011 2011 2011 2012 2012 2012 2013 2014 Memorial Sloan Kettering Beene Symposium, New York, USA MDAnderson Oncology Lecture, Houston, USA Expedition Inspiration Fund for Breast Cancer Research, 13th Ann Meeting, Sun Valley, USA Indiana University, Gladstein Award Lecture, Indianapolis, USA NCI Translational Genomics, Bethesda, USA Institute of Medicine, Workshop on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials, Washington DC, USA NCI Translational Sciences Meeting, Washington, DC Selventa Symposium, Role of Systems Biology in Personalized Medicine, Princeton, USA Association of American Cancer Institutes (AACI)/Cancer Center Administrators Forum (CCAF) Annual Meeting, Washington, DC Institute of Medicine Roundtable on Translating Genomic-Based Research for Health workshop, Washington DC American Radium Society Conference, keynote address, Las Vegas, USA NCI-Dream Summit Meeting, Bethesda, MD Sage Bionetworks Commons Congress, San Francisco, USA National Biomarker Development Alliance, Phoenix, USA Genomic Technologies and Biomaterials for Understanding Disease Conference, San Diego, USA REGIONAL AND OTHER INVITED PRESENTATIONS 2003 2009 2009 2009 2010 2010 2010 2010 2011 2011 2011 2011 2011 2011 2011 2011 2012 2012 2012 2012 2012 2012 2012 2013 2013 2013 2013 2013 2013 2013 2013 2013 2014 AVON Breast Cancer Meeting, San Francisco, USA UCSF Breast Oncology Program Scientific Retreat, San Francisco, USA UCSF Breast Oncology Program Seminar, San Francisco, USA UCSF Radiology Grand Rounds, San Francisco, USA UCSF Breast Oncology Program Scientific Retreat, San Francisco, USA UCSF Breast Oncology Program Advocacy Retreat, San Francisco, USA UCSF Breast Oncology Program Course: Biology of Breast Cancer, San Francisco, USA UCSF Radiation Oncology Course, San Francisco, USA UCSF Breast Oncology Program Scientific Retreat, San Francisco, USA UCSF Breast Oncology Program Seminar, San Francisco, USA Johns Hopkins Pathology Grand Rounds, Molecular Biomarkers for Risk and Therapeutic Response in Breast Cancer, Baltimore, MD, USA Johns Hopkins Breast Cancer Program, Breast Cancer Biology Trumps Staging, Baltimore, MD, USA Stanford Cancer Center, MammaPrint presentation, Stanford, USA I-SPY Precompetitive Collaborations, Sausalito, USA UCSF Biomedical Sciences seminar, Breast Cancer trumps staging, San Francisco, USA Taste for the Cure Science Day, San Francisco UCSF Breast Oncology Program Scientific Retreat, San Francisco, USA Athena Breast Health Network, Irvine, USA UC Berkeley, California Institute for Quantitative Biosciences, Anti-Medical School Seminar, Berkeley, USA UCSF Brain SPORE Seminar, San Francisco, USA UCSF Pharmaceutical Sciences and Pharmacogenetics Graduate Student Seminar, San Francisco, USA UCSF-LBNL Workshop Precision Medicine Big Data, San Francisco, USA UC Santa Cruz Storage Systems Research Center, Santa Cruz, USA UCSF Breast Oncology Program Scientific Retreat, San Francisco, USA UCSF Dermatology Pathology Research in Progress Seminar, San Francisco, USA UCSF Biomedical Sciences Graduate Program seminar, San Francisco, USA UCSF Breast Oncology Program Seminar, San Francisco, USA UC Athena Breast Health Network, Sacramento, USA Baylor College Cancer Center Seminar, Houston, USA UCSF 3DMedical School, San Francisco, USA UC Athena Breast Health Network, San Diego, USA Oregon Health Sciences University, Portland, USA UCSF Breast Oncology Program Scientific Retreat, San Francisco, USA GOVERNMENT and OTHER PROFESSIONAL SERVICE: Page 7 of 38 Laura J. van ‘t Veer – CV (See Professional Organizations: Service to Professional Organizations – for Netherlands government services, 2002 – 2010) UNIVERSITY AND PUBLIC SERVICE UNIVERSITY SERVICE SYSTEMWIDE: 2010-present Member UC Athena Breast Health Network UCSF CAMPUSWIDE: 2011-present Principal Investigator, Athena Breast Health Network UCSF site 2011-present Member, Chancellor’s Committee Enabling Technologies Advisory Committee 2012-present Member, UCSF Precision Medicine Platform; Chair Knowledge Cancer Network; Member Genome Medicine SCHOOL OF MEDICINE: 2010-present Associate Director, UCSF Helen Diller Family Comprehensive Cancer Center 2010-present Applied Genomics Director, UCSF Helen Diller Family Comprehensive Cancer Center 2010-present Breast Oncology Program Leader, UCSF Helen Diller Family Comprehensive Cancer Center 2010-present Member, Breast Oncology Tumor Board 2010-present Member, Breast Oncology Site Committee 2010-present Chair, UC Athena Breast Health Network Site Steering Committee 2010-present Chair, Executive Committee UCSF Breast SPORE (NCI) 2010-present Member, Recruitment Committee for faculty appointments in Departments of Pathology, Gynecology, Hematology-Oncology, Radiology 2011-present Member, Recruitment Committee for faculty appointments in Breast Surgery 2011-present Member, UCSF Helen Diller Family Comprehensive Cancer Center Development Therapeutics Program 2011-present Member, Biomedical Sciences Graduate Program 2011-present Member, UCSF Helen Diller Family Comprehensive Cancer Center Investigational Trials Resource Steering Committee 2012-present Pharmaceutical Sciences and Pharmacogenomics Graduate Program (PSPG) 2012-present Member, Helen Diller Comprehensive Cancer Center Genome Core Advisory Group PUBLIC SERVICE: Page 8 of 38 Laura J. van ‘t Veer – CV 2005, 2007, 2009 2011, 2012, 2013 2012 2013 Co-Organizer ‘Market Plaza Cancer Genomics’; Dutch Cancer Society, Cancer Genomics Center, Cancer Patient Advocacy Groups Co-Organizer ‘Taste for the Cure Science Day’, Breast Care Center, Advocacy groups, Athena Breast Health Network Presenter for Bay Area Breast Cancer Forum, “Inherited and Acquired Genetic Aspects of Breast Cancer”. A gathering of health care providers, researchers, patients, patient advocates, friends and families. April 25. Panel presenter on KALW City Vision radio show speaking on Personalized Medicine and Cancer. July 15. SUMMARY OF SERVICE ACTIVITIES: Laura van ‘t Veer serves on the Helen Diller Family Comprehensive Cancer Center Directors’ Group and is Director of the Applied Genomics Laboratory. In this role, Dr. van ‘t Veer is spearheading the establishment of an Applied Genomics for the University. She is chairing the UCSF efforts to establish next generation sequencing and is also leading acquisition of new technologies into the Applied Genomics Laboratory for University. Dr. van ‘t Veer is also a member of the Chancellor’s Advisory Committee addressing Enabling Technologies. Dr. van ‘t Veer also serves on several Departmental committees as a member of the Recruitment Committee for Pathology, Gynecology, Hematology-Oncology, as well as for Breast Surgery new Faculty recruits to the University. Dr. van ‘t Veer serves on the American Association of Cancer Research (AACR) Board of Directors, as well as an AACR Task Force on Regulatory Science and Policy. She also serves on several International Conference Planning Committees including the San Antonio Breast Cancer Symposium and the AACR annual meeting. Dr. van ‘t Veer is the Lead Organizer of UCSF Breast Oncology Program events including the annual scientific conference and weekly scientific seminar series. Dr. van ‘t Veer is co-organizer of the Taste for the Cure annual event that promotes healthy living options and features science exhibits as well as breast cancer survivorship resources and latest research findings. TEACHING and MENTORING FORMAL SCHEDULED CLASSES FOR UCSF STUDENTS: Qtr Academic Yr Course No. & Title Teaching Contribution Units Class Size Sp 2009-2010 Lab Med 180.03, Biology of Breast Cancer Lead lecture on Prognostic Markers: Development & Validation 1.5 25 Fa 2010-2011 Lab Med 180.04, Breast Cancer: From Basics to Beyond Executive Course Planning Committee Member, Leading lecture on Prognostic and Predictive Markers 1.5 25 FORMAL TEACHING IN THE NETHERLANDS 1979 – 1984 Teaching Assistant, undergraduate students Biology, Dept. of Zoology, University of Amsterdam Numerous Lecturer, undergraduate and graduate courses on Molecular Genetics of Cancer 1998 Co-organizer, The Netherlands Cancer Institute: OOA-graduate course: Clinical and Genetic Aspects of Breast Cancer 2005 Co-organizer, The Netherlands Cancer Institute: OOA-graduate course: Clinical and Genetic Aspects of Breast Cancer PREDOCTORAL STUDENTS SUPERVISED OR MENTORED Program or Dates Name School Faculty Role Title of Research Project 1995 – 2000 Mariska van Dijk Endocrine resistance in breast cancer NKI PhD Advisor Page 9 of 38 Current Position Died 2003 Laura J. van ‘t Veer – CV 2001 – 2007 Alina Vrieling NKI PhD Advisor Insulin Growth factor system and cancer risk 2001 – 2005 Britta Weigelt NKI PhD Advisor Molecular Characterization Assistant Professor, MSKCC, New York of Breast Cancer Metastasis 2002 – 2009 Marielle Ruijs NKI PhD Advisor Li-Fraumeni Syndrome Clinical Geneticist, NKI 2004 – 2009 Marleen Kok NKI PhD Advisor Endocrine resistance in breast cancer Training Medical Specialist – Medical Oncology 2005 – 2009 Stella Mook NKI PhD Advisor Risk assessment in breast cancer Training Medical Specialist – Radiotherapy 2007 – 2010 Sjoerd Bruin NKI PhD Advisor Molecular prediction of colon cancer recurrence Surgeon 2013 – 2017 Evelyn Lee UCSF PSDG PhD Advisor Gene network for metastasis PhD program POSTDOCTORAL FELLOWS AND RESIDENTS SUPERVISED OR MENTORED Program or Dates Name School Faculty Role Title of Research Project Postdoctoral fellow, DKFZ, Heidelberg, Germany Current Position 1996 -2000 Caro Lambrechts NKI Postdoc researcher Research Supervision and Career Advisor Minimal residual disease detection Left academia 1997 - 2006 Annegien Broeks NKI Postdoc researcher Research Supervision and Career Advisor Radiation- induced breast cancer Senior Research Associate, Netherlands Cancer Institute 1999 - 2003 Annuska Glas NKI Postdoc researcher Research Supervision and Career Advisor Follicular Lymphoma Director Bioinformatics Agendia BV, The Netherlands 2001 - 2007 Dorien Voskuil NKI Postdoc researcher Research Supervision and Career Advisor Insulin Growth Factor System and Cancer Risk Research Associate, EMGO-VUMC and NKI, The Netherlands 2002 - 2009 Marjanka Schmidt NKI Postdoc researcher Research Supervision and Career Advisor Breast Cancer Survival for Junior Group Leader, BRCA1/2 Carriers Netherlands Cancer Institute 2005 - 2007 Britta Weigelt NKI Postdoc researcher Research Supervision and Career Advisor Molecular Characterization Assistant Professor, of Histological Types of MSKCC, New York Breast Cancer 2006 - 2009 Tim Molloy NKI Postdoc researcher Research Supervision and Career Advisor Minimal residual disease detection Postdoc, Sydney, Australia 2007 - 2010 Youji He NKI Postdoc researcher Research Supervision and Career Advisor Rectal Cancer recurrence molecular markers Professor, Department of Immunology, Southeast University Medical School, Nanjing, China 2009 - 2011 Lorenza NKI Postdoc Mittempergher researcher Research Supervision and Career Advisor Molecular Markers for late Postdoc, TI-Pharma, metastasis in breast cancer Netherlands Page 10 of 38 Laura J. van ‘t Veer – CV 2010 present Aaron Boudreau UCSF Postdoc Research Supervision and researcher Career Advisor Breast Cancer Specific Postdoc, UCSF Tumor-Microenvironment test system development for the evaluation of drug response 2011 - 2012 Anneleen Daemen UCSF Postdoc Research Supervision and researcher Career Advisor Computational Scientist, Cross-platform pathwayGenentech based analysis identifies markers of response to the PARP inhibitor Olaparib 2011 - 2013 Nikoletta Sidiropoulos UCSF Pathology Fellow Research Supervision and Career Advisor Development of FNA for Molecular Diagnostic Assays Molecular Genetic Pathologist, University of Vermont, Burlington UCSF Pathology Fellow Research Supervision and Career Advisor Development of FNA for Molecular Diagnostic Assays Pathology Fellow, UCSF 2013 present Nancy Joseph INFORMAL TEACHING 2011-present CLIA Applied Genomics (weekly meetings) 2011-present Molecular Biomarker working group (twice monthly meetings) 2011 Annual Laboratory Retreat, October 2011 FACULTY MENTORING FACUTLY MENTORED Dates Name Position while Mentored Mentoring Role 2006-2010 Eveline Bleiker Post doctoral fellow, Junior Group Leader Career 2008-2010 Fijs van Leeuwen Postdoctoral fellow Career 2007-2010 Annegien Broeks Senior Research Associate Career 2009-2010 Marjanka Schmidt Senior Research Associate Career 2010-present Lamorna BrownSwigart Assistant Adjunct Professor Career OTHER VISITING FACULTY SUPERVISED Page 11 of 38 Current Position Group Leader Psychosocial Research, Netherlands Cancer Institute Senior Research Associate, Netherlands Cancer Institute Senior Research Associate, Netherlands Cancer Institute Senior Research Associate, Netherlands Cancer Institute Assistant Adjunct Professor, Laboratory Medicine Laura J. van ‘t Veer – CV 2011-2012 2011-2013 Sjoerd Elias Miki Mori Epidemiologist, University of Utrecht Surgeon, Showa University, Tokyo SUMMARY OF TEACHING HOURS: 2011-12: 550 total hours of teaching (including preparation) Lead coordinator of CME accredited Breast Oncology Program Scientific Retreat: 20 hours Mentoring/training postdocs in CLIA/CMO research group: 160 hours Mentoring/training postdocs and specialists in biomarkers research group: 160 hours Mentoring/training fellow in FNA Molecular testing: 80 hours Mentoring/training postdocs and researchers in drug response predictors: 150 hours 2012-13: 500 total hours of teaching (including preparation) Lead coordinator of CME accredited Breast Oncology Program Scientific Retreat: 20 hours Mentoring/training postdocs in Applied Genomics: 160 hours Mentoring/training postdocs and specialists in individual research projects: 160 hours Mentoring/training postdocs in drug response predictors: 160 hours ANTICIPATED 2013-2014: 500 total hours of teaching (including preparation) Lead coordinator of CME accredited Breast Oncology Program Scientific Retreat: 20 hours Mentoring/training postdocs in Applied Genomics: 160 hours Mentoring/training postdocs and specialists in individual research projects: 160 hours Mentoring/training postdocs in drug response predictors: 160 hours TEACHING NARRATIVE Laura van ‘t Veer has been a lecturer for numerous undergraduate, masters, and graduate level courses for various Universities in the Netherlands for over 15 years. Dr. van ‘t Veer currently mentors 2 post-docs, 2 bioinformatics researchers, 3 clinical laboratory scientists, 1 faculty member, 1 master’s student, 1 visiting researcher, 2 breast care center interns and several technicians working in her laboratory. Dr. van ‘t Veer leads weekly and bi-weekly project-specific meetings where lab members present their research in a safe and interactive environment for continual input and collaborative networking. Dr. van ‘t Veer also holds one-on-one progress meetings to discuss the development of specific projects. As the Leader of the UCSF Breast Oncology Program, Dr. van ‘t Veer is lead coordinator of the for-credit Breast Cancer Course offered through Laboratory Medicine where she organizes the overall syllabus and presents on a research topic. She is also the lead coordinator for the CME accredited annual Breast Oncology Program Scientific Retreat. RESEARCH AND CREATIVE ACTIVITIES RESEARCH AWARDS AND GRANTS ACTIVE Vons/Safeway Foundation (Esserman, UC Systemwide) 01/01/2010 – 12/31/2014 2.40 Calendar ATHENA Breast Care Network $2,500,000 The mission of Athena Breast Care Network is to save lives by transforming how care is delivered today, learn from patients, create life-changing science, and improve prevention and treatment options tomorrow. Role: Site PI Foundation National Institutes of Health, FNIH (Esserman) 04/01/2010-04/01/2015 1.80 Calendar I-SPY 2 TRIAL $5,020,383 Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis. The aim is to implement and explore biomarkers of therapeutic response in neo-adjuvant breast cancer. Role: Co-Investigator, Chair Biomarker Committee 2P30 CA82103 (McCormick) 08/05/1999 – 05/31/2017 Page 12 of 38 3.60 Calendar Laura J. van ‘t Veer – CV NIH/NCI $4,303,293 Cancer Center Support Grant The Cancer Center Support Grant provides support for administration and infrastructure for the UCSF Helen Diller Family Comprehensive Cancer Center. Dr. van ‘t Veer is the Program Leader of the Breast Oncology Program, Associate Director of the Helen Diller Family Comprehensive Cancer Center and Director of Applied Genomics. Role: Program Leader and Associate Director 180B-0065 (Esserman) 08/01/2012-07/31/2015 0.60 Calendar California Breast Cancer Research Program (CBCRP) $793,127 Predicting Breast Cancer Recurrence to Improve Care The goal is to validate a set of clinical and molecular predictors to determine the overall likelihood and timing of breast cancer recurrence. Role: Co-Investigator 1U01CA151235-01A1 (Hylton) 9/26/2011-8/31/2016 0.36 Calendar NIH $445,732 Quantitative Imaging for Assessing Breast Cancer Responses to Treatment The goal of this project is the improved integration of MRI-based quantitative imaging (QI) for evaluating response to treatment in clinical trials of women receiving pre-operative (neoadjuvant) treatment for breast cancer. Role: Co-Investigator FUTURE ACTIVE SUPPORT UCSF-PUMCH RAP (van ‘t Veer) 12/1/2013-07/30/2015 0.30 Calendar Breast Cancer Risk Assessment in Chinese Women $100,000 A Peking Union Medical College Hospital (PUMCH) – University of California San Francisco (UCSF) collaborative study. Role: PI U01 CA164720 (Bild) 07/01/2012-06/30/2017 0.60 Calendar University of Utah (NIH/NCI Prime) $624,117 (Yr 4 & 5 on project) Integrative signaling models to decipher complex cancer phenotypes The overall goal of this research is to identify core signaling pathways that contribute to cancer growth and development, and to develop models to accurately determine optimal therapeutic regimens for cancer patients. PENDING 1 U54 HG007990-01 (Haussler/van ‘t Veer/Patterson) 07/01/2014-06/30/2017 2.4 Calendar NIH $950,250 UCSC Center of Excellence for Big Data Computing in the Biomedical Sciences Create and benchmark a globally accepted set of Data Models, Application Programming Interfaces (APIs) and Bioinformatics Tools for exchange and analysis of genomic and related data that can efficiently, securely and responsibly handle data from millions of individuals. Basser Team Science Award (Esserman) 09/01/2014-08/31/2016 0.24 Calendar Basser Research Center for BRCA $1,000,000 Optimizing DNA Repair Signatures for the Use of PARP Inhibitors and Accelerating their Path to Clinical Use for Early Stage Breast Cancer The major goals of this project are to develop optimal biomarkers for patient selection, maximize response, minimize toxicity, and dramatically shorten the time to get a potent PARP inhibitor into the clinic to the patients who will benefit most. U01 CA187945 (Esserman) 07/01/2014-06/30/2019 0.60 Calendar NIH/NCI $3,369,738 Modeling the Impact of Targeted Therapy based on Breast Cancer Subtypes. This project address the question of how the introduction of new marker-treatment combinations are impacting breast cancer mortality rates on the population level and whether the new targeted therapies are cost-effective. CURRENT, THE NETHERLANDS (scientific work at the Netherlands Cancer Institute are fully covered, no grant support is used towards PI salary.) Page 13 of 38 Laura J. van ‘t Veer – CV 1. EU 7th Framework Large Scale Integrating Project Health LSHC (van’t Veer) Collaborative Oncological Gene-Environment Study (COGS) (WP 5 coordinator) 2009-2013 €202,200 direct yrs 1 - 4 COMPLETED 20MB-0001 (van ‘t Veer) 02/06/2014-03/07/2014 .3 Calendar UCSF Breast Oncology Program Scientific Retreat $8,142 This funding supports the two-day UCSF Breast Oncology Program Scientific Research Retreat. A two day conference that brings together a diverse community of individuals from UCSF and the Bay Area to learn about current breast cancer research from a variety of specialties. Role: PI P50 CA58207 (van ‘t Veer) 09/30/1992-11/30/2013 2.40 Calendar NIH/NCI One year no cost extension Bay Area Breast Cancer SPORE $2,300,000 The program aims to improve diagnosis, prognostication and therapy of breast cancer. It focuses on new therapeutic approaches to breast cancer treatment and prevention using molecular insights. Role: PI W81XWH-07-1-0663 -BC061995 (Gray) 06/20/2008-09/16/2013 0.48 Calendar US Army Medical Research & Material Command $296,040 (USAMRMC) Early Detection of Metastasis-Prone Breast Cancers The aim of this multi-institutional project is to develop anatomic and histologic molecular imaging strategies for early detection of metastasis prone breast cancers. Role: Co-Investigator R21CA152499-01 (Park) 07/28/2010-06/30/2013 0.60 Calendar NIH/NCI $130,500 Stromal MRI characteristics & gene expression profiles as predictors of outcome The goal of this project is to use MRI technology and gene expression array profiles to be able to further risk stratify patients for risk for local recurrence to identify those who can forego radiotherapy post-mastectomy. Role: Co-Investigator UCOP Multicampus Award Research Program Initiative (Esserman, UC Systemwide) 01/01/2010 – 12/31/2012 ATHENA Breast Health Network This project is a University of California (UC) initiative to accelerate advancements in breast cancer prevention, screening, and treatment. ATHENA will involve 150,000 women throughout California who will be screened for breast cancer and followed for several decades through the five UC medical centers at Davis, Irvine, Los Angeles, San Diego, and San Francisco. Role: Site PI SU2C-AACR-DT0409-02 (Slamon) 10/01/2009 – 09/30/2012 AACR Werb, Dream Team Member An Integrated Approach to Targeting Breast Cancer Molecular Subtypes and their Resistance Phenotypes The goal is to test the efficacy of individualized treatment of drug-resistant metastatic breast cancers using therapies selected based on the “omic” features of the metastatic tumors. Role: Project Co-Investigator (van ‘t Veer) 04/16/2012 – 04/15/2013 Friends for an Earlier Breast Cancer Test Detecting the Early Oncogenic Kinome Signature of Breast Cancer This project seeks to identify immediately relevant patterns of oncogenic kinases regulating tumorigenesis to support earlier detection and guide therapeutic interventions to improve outcomes. Role: PI COMPLETED, THE NETHERLANDS Page 14 of 38 Laura J. van ‘t Veer – CV 1. Dutch Top Institute Pharma, project T3.8 (van’t Veer) Microarray profiling for drug Response. 2007-2011 €850,000 direct yrs 1 - 5 2. EU 6th framework Network of excellence (van’t Veer) TRANSBIG,LSHC-CT-2004-018911 Microarray Profiling in Node Negative Breast Cancer (Pilot studies for MINDACT) (Transbig Correlative Science) 2004-2011 €357,000 direct yrs 1 - 8 3. Dutch Cancer Society; NKI 2007-3839 (van’t Veer) Genetic determinants of survival and second breast cancer development in premeno-pausal breast cancer patients. 2007-2010 €485,000 direct yrs 1 – 4 4. Netherlands Genomics Initiative (van’t Veer) Center for Cancer Genomics. (WP coordinator) 2008-2012 €1,500,000 direct yrs 1 – 5 (discontinued after 12/31/2010) 5. EU 6th Framework STREP; DISMAL, LSHC-CT-2005-018911 (van’t Veer) Detection of minimal tumor cell admixture in bone marrow and peripheral progenitor cell preparations of patients with breast cancer. (WP Participant) 2005-2009 €262,500 direct yrs 1 - 4 6. Functional activity of the estrogen receptor in human breast cancer. (Dutch Cancer Society (DCS), NKI 96-1268; L.J. van’t Veer, H. Bartelink), ended 2001. 7. Detection of minimal tumor cell admixture in bone marrow and peripheral progenitor cell preparations of patients with breast cancer. (Organon Teknika 95-97) (DCS NKI 97-1468; S. Rodenhuis, L.J. van’t veer) (EU 6th framework STREP: DISMAL, LSHC-CT2005-018911, K. Pantel, co-PI) 8. Genetic profiling of tumors from patients with a genetic susceptibility for breast cancer. (DCS, NKI 01-2424; P.M. Nederlof, S. Verhoef, L.J. van’t Veer), as co-PI, ended 2005 9. Microarray analysis of (breast) cancer as a diagnostic tool to guide optimal treatment. (DCS, Program NKI 02-2575; M.J. van de Vijver, H. Bartelink, L.J. van’t Veer), (Collaborative program with Rosetta Inpharmatics, Kirkland, USA, Dr S.H. Friend), (Collaborative program with Delft Technical University, Information Theory Group,Dr L.F.A. wessels) (‘Regie-orgaan Genomics’ 02-01, Cancer Genomics Zwaartepunt, A. Berns: Program Director Molecular Profiling, L.J. van’t Veer) (EU 6th framework Network of excellence: TRANSBIG,LSHC-CT-2004-503426, M. Piccart, Program Director Biotechnology L.J. van’t Veer) (Dutch Top Institute Pharma, project T3.8 2007-2011: Therapy response profiling; L.J. van’t Veer, E.M. Berns) (‘Regie-orgaan Genomics’ 08, Cancer Genomics Zwaartepunt, H. Bos: Program Director Molecular Profiling, L.J. van’t Veer) 10. The contribution of ATM heterozygosity to the risk of radiation-induced breast cancer. (‘Startgeld’ NKI, NKI 96-1; DCS, NKI 97-1430; L.J. van’t Veer, N.S. Russell, F.E. van Leeuwen; DCS, NKI 01-2425; A. Broeks, L.J. van’t Veer, F.E. van Leeuwen) 11. Risk assessment and gene-environment interactions in breast and/or ovarian cancer families. (DCS, NKI 98-1854; F.E. van Leeuwen, L.J. van’t Veer and The Netherlands Collaborative Group on Hereditary Breast Cancer; DCS, NKI 04-3088; F.E. van Leeuwen, M. Rookus, L.J. van’t Veer) 12. Clinical outcome of breast cancer in BRCA1 and BRCA2 carriers. (DCS, NKI 01-2423; L.J. van’t Veer, R.A.E.M. Tollenaar) continued in 9. 13. Genetic determinants of risk, survival and second breast cancer development in premeno-pausal breast cancer patients. (DCS, NKI 2007-3839; M.K. Schmidt, L.J. van’t Veer, R.A.E.M. Tollenaar)(EU 7th framework Large Scalle Integrating Project: COGS, P. Hall and D. Easton, WP coordinator Tumor Biology: L.J. van’t Veer) Page 15 of 38 Laura J. van ‘t Veer – CV 14. Avoidance of overtreatment with radiotherapy in rectal cancer. (DCS, NKI 07-3945;C.A.M. Marijnen, L.J. van’t Veer, C.J.H. van de Velde) 15. Genomic factors for the prediction of colon cancer recurrence. (L.J. van’t Veer, M.L. van Velthuysen, C.A.M. Marijnen, R.A.E.M. Tollenaar) 16. Prophylactic surgery in carriers of BRCA1 and BRCA2 mutations. (Private Fund 1999) (NIH, RO1-CA83855 to T. R. Rebbeck-UPENN (PI); subcontract) (EORTC Hereditary breast cancer project, 02-04, R.A.E.M. Tollenaar, L.J. van’t Veer), ended 2003 17. The Insulin-like growth factor (IGF) system in breast and colorectal carcinogenesis: dietary intervention and molecular studies. (DCS, NKI 01-2579; D.W. Voskuil, L.J. van’t Veer, E. Kampman) ended mid 2007 PEER REVIEWED PUBLICATIONS: 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. Heyting, C. & van ‘t Veer, L.J. Repair of ethylnitrosourea-induced DNA damage in the newborn rat. II. Localization of unscheduled DNA synthesis in the developing rat brain. Carcinogenesis 2, 1173-80 (1981)PMID:7318154 van Raamsdonk, W., van ‘t Veer, L.J., Te Kronnie, G., Mos, W., Van der Laan, W. & Van der Stelt, A. Movements and innervation as determining factors in the development of vertebrae skeletal muscle. . J Anat 133, 130-134 (1981) van Raamsdonk, W., van ‘t Veer, L.J., Veeken, K., Te Kronnie, G. & de Jager, S. Fiber type differentiation in fish. Molec Physiol 2, 31-47 (1982) van Raamsdonk, W., van ‘t Veer, L.J., Veeken, K., Heyting, C. & Pool, C.W. Differentiation of muscle fiber types in the teleost Brachydanio rerio, the zebrafish. Posthatching development. Anatomy and embryology 164, 51-62 (1982)PMID:7114488 van ‘t Veer, L.J., Veeken, K. & van Raamsdonk, W. The specific contractile properties of skeletal muscles of vertebraes. Acta Morphol Neerl Scan 21, 177-178 (1983) Nusse, R., van ‘t Veer, L.J., Geurts van Kessel, A., Van Agthoven, A., Bootsma, D. & Varmus, H. Chromosomal localization of a human homolog of a putative mammary-tumor oncogene. Cytog C Gen 37, 556-557 (1984) van ‘t Veer, L.J., van Kessel, A.G., van Heerikhuizen, H., van Ooyen, A. & Nusse, R. Molecular cloning and chromosomal assignment of the human homolog of int-1, a mouse gene implicated in mammary tumorigenesis. Mol Cell Biol 4, 2532-4 (1984).PMC:369085 PMID:6513929 van Ooyen, A., van ‘t Veer, L.J., van Heerikhuizen, H. & Nusse, R. Structural analysis of the murine int-1 gene, a putative mammary oncogene. UCLA Symposium Mol Cell Biol 17, 451-459 (1984) Nusse, R., van Ooyen, A., Rijsewijk, F., van Lohuizen, M., Schuuring, E. & van ‘t Veer, L.J. Retroviral insertional mutagenesis in murine mammary cancer. Proceedings of the Royal Society of London. Series B, Containing papers of a Biological character. Royal Society 226, 3-13 (1985)PMID:2866522 Kuppen, P.J., Schuitemaker, H., van ‘t Veer, L.J., de Bruijn, E.A., van Oosterom, A.T. & Schrier, P.I. cisdiamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. Cancer Res 48, 3355-9 (1988)PMID:2897238 van ‘t Veer, L.J., Hermens, R., van den Berg-Bakker, L.A., Cheng, N.C., Fleuren, G.J., Bos, J.L., Cleton, F.J. & Schrier, P.I. ras oncogene activation in human ovarian carcinoma. Oncogene 2, 157-65 (1988)PMID:3285294 van ‘t Veer, L.J., van den Berg-Bakker, L.A., Hermens, R.P., Deprez, R.L. & Schrier, P.I. High frequency of mas oncogene activation detected in the NIH3T3 tumorigenicity assay. Oncogene Res 3, 247-54 (1988)PMID:3060802 van ‘t Veer, L.J., Burgering, B.M., Versteeg, R., Boot, A.J., Ruiter, D.J., Osanto, S., Schrier, P.I. & Bos, J.L. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol 9, 3114-6 (1989).PMC:362784 PMID:2674680 Rustgi, A.K., van ‘t Veer, L.J. & Bernards, R. Two genes encode factors with NF-kappa B- and H2TF1-like DNA-binding properties. Proc Natl Acad Sci U S A 87, 8707-10 (1990).PMC:55028 PMID:2247438 Schrier, P.I., Versteeg, R., Peltenburg, L.T., Plomp, A.C., van ‘t Veer, L.J. & Kruse-Wolters, K.M. Sensitivity of melanoma cell lines to natural killer cells: a role for oncogene-modulated HLA class I expression? Semin Cancer Biol 2, 73-83 (1991)PMID:1912519 van ‘t Veer, L.J., Lutz, P.M., Isselbacher, K.J. & Bernards, R. Structure and expression of major histocompatibility complex-binding protein 2, a 275-kDa zinc finger protein that binds to an enhancer of major histocompatibility complex class I genes. Proc Natl Acad Sci U S A 89, 8971-5 (1992).PMC:50046 PMID:1409593 Page 16 of 38 Laura J. van ‘t Veer – CV 17. Hateboer, G., Timmers, H.T., Rustgi, A.K., Billaud, M., van ‘t Veer, L.J. & Bernards, R. TATA-binding protein and the retinoblastoma gene product bind to overlapping epitopes on c-Myc and adenovirus E1A protein. Proc Natl Acad Sci U S A 90, 8489-93 (1993).PMC:47382 PMID:7690963 18. van ‘t Veer, L.J., Beijersbergen, R.L. & Bernards, R. N-myc suppresses major histocompatibility complex class I gene expression through down-regulation of the p50 subunit of NF-kappa B. EMBO J 12, 195-200 (1993).PMC:413191 PMID:8428579 19. van ‘t Veer, L.J., van der Feltz, M.J., van den Berg-Bakker, C.A., Cheng, N.C., Hermens, R.P., van Oorschot, D.A., Kievits, T. & Schrier, P.I. Activation of the mas oncogene involves coupling to human alphoid sequences. Oncogene 8, 2673-81 (1993)PMID:8378079 20. Hijmans, E.M., Voorhoeve, P.M., Beijersbergen, R.L., van ‘t Veer, L.J. & Bernards, R. E2F-5, a new E2F family member that interacts with p130 in vivo. Mol Cell Biol 15, 3082-9 (1995).PMC:230539 PMID:7760804 21. Wolthuis, R.M., Bauer, B., van ‘t Veer, L.J., de Vries-Smits, A.M., Cool, R.H., Spaargaren, M., Wittinghofer, A., Burgering, B.M. & Bos, J.L. RalGDS-like factor (Rlf) is a novel Ras and Rap 1A-associating protein. Oncogene 13, 353-62 (1996)PMID:8710374 22. Alkema, M.J., Bronk, M., Verhoeven, E., Otte, A., van ‘t Veer, L.J., Berns, A. & van Lohuizen, M. Identification of Bmi1interacting proteins as constituents of a multimeric mammalian polycomb complex. Genes Dev 11, 226-40 (1997)PMID:9009205 23. de Jong, D., Richel, D.J., Schenkeveld, C., Boerrigter, L. & van ‘t Veer, L.J. Oligoclonal peripheral T-cell lymphocytosis as a result of aberrant T-cell development in a cortical thymoma. Diagn Mol Pathol 6, 244-8 (1997)PMID:9360846 24. de Lange, M.S., Top, B., Lambrechts, C., Maas, R.A., Peterse, H.L., Mooi, W.J., van ‘t Veer, L.J. & Rodenhuis, S. A method to monitor mRNA levels in human breast tumor cells obtained by fine-needle aspiration. Diagn Mol Pathol 6, 353-60 (1997)PMID:9559296 25. Peelen, T., Van Vliet, M., Petrij-Bosch, A., Mieremet, R., Szabo, C., Van Den Ouweland, A.M.W., Hogervorst, F., Brohet, R., Ligtenberg, M.J.L., Teugels, E., Van Der Luijt, R., Van Der Hout, A.H., Gille, J.J.P., Pals, G., Jedema, I., Olmer, R., Van Leeuwen, I., Newman, B., Plandsoen, M., Van Der Est, M., Brink, G., Hageman, S., Arts, P.J.W., Bakker, M.M., Willems, H.W., Van Der Looij, E., Neyns, B., Bonduelle, M., Jansen, R., Oosterwijk, J.C., Sijmons, R., Smeets, H.J.M., Van Asperen, C.J., Meijers-Heijboer, H., Klijn, J.G.M., De Greve, J., King, M.C., Menko, F.H., Brunner, H.G., Halley, D., Van Ommen, G.J.B., Vasen, H.F.A., Cornelisse, C.J., van ‘t Veer, L.J., De Knijff, P., Bakker, E. & Devilee, P. A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. American Journal of Human Genetics 60, 1041-1049 (1997) 26. Petrij-Bosch, A., Peelen, T., Van Vliet, M., Van Eijk, R., Olmer, R., Drüsedau, M., Hogervorst, F.B.L., Hageman, S., Arts, P.J.W., Ligtenberg, M.J.L., Meijers-Heijboer, H., Klijn, J.G.M., Vasen, H.F.A., Cornelisse, C.J., van ‘t Veer, L.J., Bakker, E., Van Ommen, G.J.B. & Devilee, P. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nature Genetics 17, 341-345 (1997) 27. Rodenhuis, S., Boerrigter, L., Top, B., Slebos, R.J., Mooi, W.J., van ‘t Veer, L.J. & van Zandwijk, N. Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 15, 285-91 (1997)PMID:8996154 28. Van Dijk, M.A.J., Floore, A.N., Kloppenborg, K.I.M. & van ‘t Veer, L.J. A functional assay in yeast for the human estrogen receptor displays wild-type and variant estrogen receptor messenger RNAs present in breast carcinoma. Cancer Research 57, 3478-3485 (1997) 29. Van Schooten, F.J., Godschalk, R.W., Breedijk, A., Maas, L.M., Kriek, E., Sakai, H., Wigbout, G., Baas, P., van ‘t Veer, L.J. & Van Zandwijk, N. 32P-postlabelling of aromatic DNA adducts in white blood cells and alveolar macrophages of smokers: saturation at high exposures. Mutation research 378, 65-75 (1997)PMID:9288886 30. Weeda, G., Rossignol, M., Fraser, R.A., Winkler, G.S., Vermeulen, W., van ‘t Veer, L.J., Ma, L., Hoeijmakers, J.H. & Egly, J.M. The XPB subunit of repair/transcription factor TFIIH directly interacts with SUG1, a subunit of the 26S proteasome and putative transcription factor. Nucleic Acids Res 25, 2274-83 (1997).PMC:146752 PMID:9173976 31. Broeks, A., De Klein, A., Floore, A.N., Muijtjens, M., Kleijer, W.J., Jaspers, N.G. & van ‘t Veer, L.J. ATM germline mutations in classical ataxia-telangiectasia patients in the Dutch population. Human Mutation 12, 330-337 (1998) 32. Ceha, H.M., Balm, A.J., de Jong, D. & van ‘t Veer, L.J. Multiple malignancies in a patient with bilateral retinoblastoma. J Laryngol Otol 112, 189-92 (1998)PMID:9578885 33. Dallinga, J.W., Pachen, D.M., Wijnhoven, S.W., Breedijk, A., van ‘t Veer, L.J., Wigbout, G., van Zandwijk, N., Maas, L.M., van Agen, E., Kleinjans, J.C. & van Schooten, F.J. The use of 4-aminobiphenyl hemoglobin adducts and aromatic DNA adducts in lymphocytes of smokers as biomarkers of exposure. Cancer Epidemiol Biomarkers Prev 7, 571-7 (1998)PMID:9681524 34. Godschalk, R.W., Maas, L.M., Van Zandwijk, N., van ‘t Veer, L.J., Breedijk, A., Borm, P.J., Verhaert, J., Kleinjans, J.C. & van Schooten, F.J. Differences in aromatic-DNA adduct levels between alveolar macrophages and subpopulations of white blood cells from smokers. Carcinogenesis 19, 819-25 (1998)PMID:9635869 Page 17 of 38 Laura J. van ‘t Veer – CV 35. Lambrechts, A.C., van ‘t Veer, L.J. & Rodenhuis, S. The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods. Ann Oncol 9, 1269-76 (1998)PMID:9932154 36. Van Zandwijk, N. & van ‘t Veer, L.J. The role of prognostic factors and oncogenes in the detection and management of non-small-cell lung cancer. Oncology (Williston Park) 12, 55-9 (1998)PMID:9516613 37. Bartelink, H., Begg, A., Martin, J.C., van Dijk, M., van ‘t Veer, L.J., van der Vaart, P. & Verheij, M. Towards prediction and modulation of treatment response. Radiother Oncol 50, 1-11 (1999)PMID:10225551 38. Laake, K., Launonen, V., Niederacher, D., Gudlaugsdottir, S., Seitz, S., Rio, P., Champème, M.H., Bièche, I., Birnbaum, D., White, G., Sztan, M., Sever, N., Plummer, S., Osorio, A., Broeks, A., Huusko, P., Spurr, N., Borg, Å., Cleton-Jansen, A.M., van ‘t Veer, L.J., Benitez, J., Casey, G., Peterlin, B., Olah, E., Varley, J., Bignon, Y.J., Scherneck, S., Sigurdardottir, V., Lidereau, R., Eyfjord, J., Beckmann, M.W., Winqvist, R., Skovlund, E. & Børresen-Dale, A.L. Loss of heterozygosity at 11q23.1 and survival in breast cancer: Results of a large European study. Genes Chromosomes and Cancer 25, 212-221 (1999) 39. Lambrechts, A.C., Bosma, A.J., Klaver, S.G., Top, B., Perebolte, L., van ‘t Veer, L.J. & Rodenhuis, S. Comparison of immunocytochemistry, reverse transcriptase polymerase chain reaction, and nucleic acid sequence-based amplification for the detection of circulating breast cancer cells. Breast Cancer Research and Treatment 56, 219-231 (1999) 40. Ligtenberg, M.J.L., Hogervorst, F.B.L., Willems, H.W., Arts, P.J.W., Brink, G., Hageman, S., Bosgoed, E.A.J., Van Der Looij, E., Rookus, M.A., Devilee, P., Vos, E.M.A.W., Wigbout, G., Struycken, P.M., Menko, F.H., Rutgers, E.J.T., Hoefsloot, E.H., Mariman, E.C.M., Brunner, H.G. & van ‘t Veer, L.J. Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2. British Journal of Cancer 79, 1475-1478 (1999) 41. Bartelink, H., Begg, A.C., Martin, J.C., van Dijk, M., Moonen, L., van ‘t Veer, L.J., Van de Vaart, P. & Verheij, M. Translational research offers individually tailored treatments for cancer patients. Cancer J Sci Am 6, 2-10 (2000)PMID:10696731 42. Broeks, A., Russell, N.S., Floore, A.N., Urbanus, J.H.M., Dahler, E.C., Van 'T Veer, M.B., Hagenbeek, A., Noordijk, E.M., Crommelin, M.A., Van Leeuwen, F.E. & van ‘t Veer, L.J. Increased risk of breast cancer following irradiation for Hodgkin's disease is not a result of ATM germline mutations. International Journal of Radiation Biology 76, 693-698 (2000) 43. Broeks, A., Urbanus, J.H.M., Floore, A.N., Dahler, E.C., Klijn, J.G.M., Rutgers, E.J.T., Devilee, P., Russell, N.S., Van Leeuwen, F.E. & van ‘t Veer, L.J. ATM-heterozygous germline mutations contribute to breast cancer- susceptibility. American Journal of Human Genetics 66, 494-500 (2000) 44. van Dijk, M.A., Hart, A.A. & van ‘t Veer, L.J. Differences in estrogen receptor alpha variant messenger RNAs between normal human breast tissue and primary breast carcinomas. Cancer Res 60, 530-3 (2000)PMID:10676630 45. Bosma, A.J., Weigelt, B., Lambrechts, A.C., Verhagen, O.J.H.M., Pruntel, R., Hart, A.A.M., Rodenhuis, S. & van ‘t Veer, L.J. Detection of circulating breast tumor cells by differential expression of marker genes. Clinical Cancer Research 8, 18711877 (2002) 46. Crul, M., de Klerk, G.J., Swart, M., van ‘t Veer, L.J., de Jong, D., Boerrigter, L., Palmer, P.A., Bol, C.J., Tan, H., de Gast, G.C., Beijnen, J.H. & Schellens, J.H. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20, 2726-35 (2002)PMID:12039935 47. Rebbeck, T.R., Lynch, H.T., Neuhausen, S.L., Narod, S.A., van ‘t Veer, L.J., Garber, J.E., Evans, G., Isaacs, C., Daly, M.B., Matloff, E., Olopade, O.I. & Weber, B.L. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. New England Journal of Medicine 346, 1616-1622 (2002) 48. van ‘t Veer, L.J. & De Jong, D. The microarray way to tailored cancer treatment. Nat Med 8, 13-4 (2002)PMID:11786894 49. Van De Vijver, M.J., He, Y.D., van ‘t Veer, L.J., Dai, H., Hart, A.A.M., Voskuil, D.W., Schreiber, G.J., Peterse, J.L., Roberts, C., Marton, M.J., Parrish, M., Atsma, D., Witteveen, A., Glas, A., Delahaye, L., Van Der Velde, T., Bartelink, H., Rodenhuis, S., Rutgers, E.T., Friend, S.H. & Bernards, R. A gene-expression signature as a predictor of survival in breast cancer. New England Journal of Medicine 347, 1999-2009 (2002) 50. Van Schooten, F.J., Besaratinia, A., De Flora, S., D'Agostini, F., Izzotti, A., Camoirano, A., Balm, A.J., Dallinga, J.W., Bast, A., Haenen, G.R., van ‘t Veer, L.J., Baas, P., Sakai, H. & Van Zandwijk, N. Effects of oral administration of N-acetyl-Lcysteine: a multi-biomarker study in smokers. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 11, 167-75 (2002)PMID:11867504 51. van ‘t Veer, L.J., Dai, H., Van de Vijver, M.J., He, Y.D., Hart, A.A.M., Mao, M., Peterse, H.L., Van Der Kooy, K., Marton, M.J., Witteveen, A.T., Schreiber, G.J., Kerkhoven, R.M., Roberts, C., Linsley, P.S., Bernards, R. & Friend, S.H. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002) 52. Wessels, L.F.A., Van Welsem, T., Hart, A.A.M., van ‘t Veer, L.J., Reinders, M.J.T. & Nederlof, P.M. Molecular classification of breast carcinomas by comparative genomic hybridization: A specific somatic genetic profile for BRCA1 tumors. Cancer Research 62, 7110-7117 (2002) Page 18 of 38 Laura J. van ‘t Veer – CV 53. Broeks, A., Urbanus, J.H.M., De Knijff, P., Devilee, P., Nicke, M., Klöpper, K., Dörk, T., Floore, A.N. & van ‘t Veer, L.J. IVS10-6T>G, an ancient ATM germline mutation linked with breast cancer. Human Mutation 21, 521-528 (2003) 54. Hogervorst, F.B., Nederlof, P.M., Gille, J.J., McElgunn, C.J., Grippeling, M., Pruntel, R., Regnerus, R., van Welsem, T., van Spaendonk, R., Menko, F.H., Kluijt, I., Dommering, C., Verhoef, S., Schouten, J.P., van ‘t Veer, L.J. & Pals, G. Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer research 63, 144953 (2003)PMID:12670888 55. Klaren, H.M., van ‘t Veer, L.J., van Leeuwen, F.E. & Rookus, M.A. Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. Journal of the National Cancer Institute 95, 941-947 (2003) 56. van ‘t Veer, L.J., Dai, H., van de Vijver, M.J., He, Y.D., Hart, A.A., Bernards, R. & Friend, S.H. Expression profiling predicts outcome in breast cancer. Breast Cancer Res 5, 57-8 (2003).PMC:154139 PMID:12559048 57. van ‘t Veer, L.J. & Weigelt, B. Road map to metastasis. Nature Medicine 9, 999-1000 (2003) 58. Weigelt, B., Bosma, A.J., Hart, A.A.M., Rodenhuis, S. & van ‘t Veer, L.J. Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. British Journal of Cancer 88, 1091-1094 (2003) 59. Weigelt, B., Bosma, A.J. & van ‘t Veer, L.J. Expression of a novel lacrimal gland gene lacritin in human breast tissues. J Cancer Res Clin Oncol 129, 735-6 (2003)PMID:14574570 60. Weigelt, B., Glas, A.M., Wessels, L.F.A., Witteveen, A.T., Peterse, J.L. & van ‘t Veer, L.J. Gene expression profiles of primary breast tumors maintained in distant metastases. Proceedings of the National Academy of Sciences of the United States of America 100, 15901-15905 (2003) 61. Broeks, A., De Witte, L., Nooijen, A., Huseinovic, A., Klijn, J.G.M., Van Leeuwen, F.E., Russell, N.S. & van ‘t Veer, L.J. Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers. Breast Cancer Research and Treatment 83, 91-93 (2004) 62. de Jong, D. & van ‘t Veer, L.J. Tools for molecular risk-stratification for clinical purposes: CLL as a prototype. European journal of human genetics : EJHG 12, 423 (2004)PMID:15162123 63. Michalides, R., Griekspoor, A., Balkenende, A., Verwoerd, D., Janssen, L., Jalink, K., Floore, A., Velds, A., van ‘t Veer, L.J. & Neefjes, J. Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer cell 5, 597-605 (2004)PMID:15193262 64. Olivier, R.I., van Beurden, M., Lubsen, M.A., Rookus, M.A., Mooij, T.M., van de Vijver, M.J. & van ‘t Veer, L.J. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. British journal of cancer 90, 1492-7 (2004).PMC:2409718 PMID:15083174 65. Rebbeck, T.R., Friebel, T., Lynch, H.T., Neuhausen, S.L., van ‘t Veer, L.J., Garber, J.E., Evans, G.R., Narod, S.A., Isaacs, C., Matloff, E., Daly, M.B., Olopade, O.I. & Weber, B.L. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22, 1055-62 (2004)PMID:14981104 66. Schmidt, M.K., Van Leeuwen, F.E., Klaren, H.M., Tollenaar, R.A.E.M. & van ‘t Veer, L.J. Genetic research with stored human tissue: A coding procedure with optimal use of information and protection of privacy. Genetisch onderzoek met opgeslagen lichaamsmateriaal: Een coderingsprocedure met optimaal gebruik van informatie bij behoud van privacy 148, 564-568 (2004) 67. Szabo, C.I., Schutte, M., Broeks, A., Houwing-Duistermaat, J.J., Thorstenson, Y.R., Durocher, F., Oldenburg, R.A., Wasielewski, M., Odefrey, F., Thompson, D., Floore, A.N., Kraan, J., Klijn, J.G., van den Ouweland, A.M., Wagner, T.M., Devilee, P., Simard, J., van ‘t Veer, L.J., Goldgar, D.E. & Meijers-Heijboer, H. Are ATM mutations 7271T-->G and IVS106T-->G really high-risk breast cancer-susceptibility alleles? Cancer Res 64, 840-3 (2004)PMID:14871810 68. van ‘t Veer, L.J. Laura van 't Veer, PhD: bringing tumor gene profiles into the clinic. Interview. JAMA 292, 675 (2004)PMID:15304450 69. Voskuil, D.W., Bosma, A., Vrieling, A., Rookus, M.A. & van ‘t Veer, L.J. Insulin-like growth factor (IGF)-system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk. Breast Cancer Res Treat 84, 225-33 (2004)PMID:15026620 70. Weigelt, B. & van ‘t Veer, L.J. Hard-wired genotype in metastatic breast cancer. Cell cycle 3, 756-7 (2004)PMID:15153810 71. Weigelt, B., Verduijn, P., Bosma, A.J., Rutgers, E.J., Peterse, H.L. & van ‘t Veer, L.J. Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers. British Journal of Cancer 90, 1531-1537 (2004) 72. Bleiker, E., Wigbout, G., van Rens, A., Verhoef, S., van ‘t Veer, L.J. & Aaronson, N. Withdrawal from genetic counselling for cancer. Hereditary cancer in clinical practice 3, 19-27 (2005).PMC:2837064 PMID:20223026 73. Chang, H.Y., Nuyten, D.S.A., Sneddon, J.B., Hastie, T., Tibshirani, R., Sørlie, T., Dai, H., He, Y.D., van ‘t Veer, L.J., Bartelink, H., Van De Rijn, M., Brown, P.O. & Van De Vijver, M.J. Robustness, scalability, and integration of a woundresponse gene expression signature in predicting breast cancer survival. Proceedings of the National Academy of Sciences of the United States of America 102, 3738-3743 (2005) 74. Dai, H., van ‘t Veer, L.J., Lamb, J., He, Y.D., Mao, M., Fine, B.M., Bernards, R., van de Vijver, M., Deutsch, P., Sachs, A., Stoughton, R. & Friend, S. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer research 65, 4059-66 (2005)PMID:15899795 Page 19 of 38 Laura J. van ‘t Veer – CV 75. Geurts, T.W., Nederlof, P.M., van den Brekel, M.W., van ‘t Veer, L.J., de Jong, D., Hart, A.A., van Zandwijk, N., Klomp, H., Balm, A.J. & van Velthuysen, M.L. Pulmonary squamous cell carcinoma following head and neck squamous cell carcinoma: metastasis or second primary? Clinical cancer research : an official journal of the American Association for Cancer Research 11, 6608-14 (2005)PMID:16166439 76. Glas, A.M., Kersten, M.J., Delahaye, L.J., Witteveen, A.T., Kibbelaar, R.E., Velds, A., Wessels, L.F., Joosten, P., Kerkhoven, R.M., Bernards, R., van Krieken, J.H., Kluin, P.M., van ‘t Veer, L.J. & de Jong, D. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 105, 301-7 (2005)PMID:15345589 77. Oestreicher, N., Ramsey, S.D., Linden, H.M., McCune, J.S., van ‘t Veer, L.J., Burke, W. & Veenstra, D.L. Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genetics in medicine : official journal of the American College of Medical Genetics 7, 380-9 (2005)PMID:16024969 78. Rebbeck, T.R., Friebel, T., Wagner, T., Lynch, H.T., Garber, J.E., Daly, M.B., Isaacs, C., Olopade, O.I., Neuhausen, S.L., van ‘t Veer, L.J., Eeles, R., Evans, D.G., Tomlinson, G., Matloff, E., Narod, S.A., Eisen, A., Domchek, S., Armstrong, K. & Weber, B.L. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23, 7804-10 (2005)PMID:16219936 79. van Asperen, C.J., Brohet, R.M., Meijers-Heijboer, E.J., Hoogerbrugge, N., Verhoef, S., Vasen, H.F., Ausems, M.G., Menko, F.H., Gomez Garcia, E.B., Klijn, J.G., Hogervorst, F.B., van Houwelingen, J.C., van ‘t Veer, L.J., Rookus, M.A. & van Leeuwen, F.E. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. Journal of medical genetics 42, 711-9 (2005).PMC:1736136 PMID:16141007 80. Van Beers, E.H., Van Welsem, T., Wessels, L.F.A., Li, Y., Oldenburg, R.A., Devilee, P., Cornelisse, C.J., Verhoef, S., Hogervorst, F.B.L., van ‘t Veer, L.J. & Nederlof, P.M. Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Research 65, 822-827 (2005) 81. van Sprundel, T.C., Schmidt, M.K., Rookus, M.A., Brohet, R., van Asperen, C.J., Rutgers, E.J., van ‘t Veer, L.J. & Tollenaar, R.A. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. British journal of cancer 93, 287-92 (2005).PMC:2361560 PMID:16052221 82. van ‘t Veer, L.J., Paik, S. & Hayes, D.F. Gene expression profiling of breast cancer: A new tumor marker. Journal of Clinical Oncology 23, 1631-1635 (2005) 83. Voskuil, D.W., Vrieling, A., van ‘t Veer, L.J., Kampman, E. & Rookus, M.A. The insulin-like growth factor system in cancer prevention: potential of dietary intervention strategies. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 14, 195203 (2005)PMID:16041870 84. Weigelt, B., Hu, Z., He, X., Livasy, C., Carey, L.A., Ewend, M.G., Glas, A.M., Perou, C.M. & van ‘t Veer, L.J. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Research 65, 9155-9158 (2005) 85. Weigelt, B., Peterse, J.L. & van ‘t Veer, L.J. Breast cancer metastasis: Markers and models. Nature Reviews Cancer 5, 591602 (2005) 86. Weigelt, B., Wessels, L.F.A., Bosma, A.J., Glas, A.M., Nuyten, D.S.A., He, Y.D., Dai, H., Peterse, J.L. & van ‘t Veer, L.J. No common denominator for breast cancer lymph node metastasis. British Journal of Cancer 93, 924-932 (2005) 87. Wessels, L.F.A., Reinders, M.J.T., Hart, A.A.M., Veenman, C.J., Dai, H., He, Y.D. & van ‘t Veer, L.J. A protocol for building and evaluating predictors of disease state based on microarray data. Bioinformatics 21, 3755-3762 (2005) 88. Andrieu, N., Easton, D.F., Chang-Claude, J., Rookus, M.A., Brohet, R., Cardis, E., Antoniou, A.C., Wagner, T., Simard, J., Evans, G., Peock, S., Fricker, J.P., Nogues, C., van ‘t Veer, L.J., Van Leeuwen, F.E. & Goldgar, D.E. Effect of chest x-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: A report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. Journal of Clinical Oncology 24, 33613366 (2006) 89. Bogaerts, J., Cardoso, F., Buyse, M., Braga, S., Loi, S., Harrison, J.A., Bines, J., Mook, S., Decker, N., Ravdin, P., Therasse, P., Rutgers, E., van ‘t Veer, L.J. & Piccart, M. Gene signature evaluation as a prognostic tool: Challenges in the design of the MINDACT trial. Nature Clinical Practice Oncology 3, 540-551 (2006) 90. Buyse, M., Loi, S., van ‘t Veer, L.J., Viale, G., Delorenzi, M., Glas, A.M., d'Assignies, M.S., Bergh, J., Lidereau, R., Ellis, P., Harris, A., Bogaerts, J., Therasse, P., Floore, A., Amakrane, M., Piette, F., Rutgers, E., Sotiriou, C., Cardoso, F., Piccart, M.J., Decker, N. & Straehle, C. Validation and clinical utility of a 70-gene prognostic signature for women with nodenegative breast cancer. Journal of the National Cancer Institute 98, 1183-1192 (2006) 91. Domchek, S.M., Friebel, T.M., Neuhausen, S.L., Wagner, T., Evans, G., Isaacs, C., Garber, J.E., Daly, M.B., Eeles, R., Matloff, E., Tomlinson, G.E., van ‘t Veer, L.J., Lynch, H.T., Olopade, O.I., Weber, B.L. & Rebbeck, T.R. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. The lancet oncology 7, 223-9 (2006)PMID:16510331 92. Fan, C., Oh, D.S., Wessels, L., Weigelt, B., Nuyten, D.S.A., Nobel, A.B., van ‘t Veer, L.J. & Perou, C.M. Concordance among gene-expression-based predictors for breast cancer. New England Journal of Medicine 355, 560-569 (2006) Page 20 of 38 Laura J. van ‘t Veer – CV 93. Glas, A.M., Floore, A., Delahaye, L.J.M.J., Witteveen, A.T., Pover, R.C.F., Bakx, N., Lahti-Domenici, J.S.T., Bruinsma, T.J., Warmoes, M.O., Bernards, R., Wessels, L.F.A. & van ‘t Veer, L.J. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 7(2006) 94. Lai, C., Reinders, M.J., van ‘t Veer, L.J. & Wessels, L.F. A comparison of univariate and multivariate gene selection techniques for classification of cancer datasets. BMC bioinformatics 7, 235 (2006).PMC:1569875 PMID:16670007 95. Loi, S., Sotiriou, C., Buyse, M., Rutgers, E., van ‘t Veer, L.J., Piccart, M. & Cardoso, F. Molecular forecasting of breast cancer: time to move forward with clinical testing. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 24, 721-2; author reply 722-3 (2006)PMID:16446348 96. Olivier, R.I., van Beurden, M. & van 't Veer, L.J. The role of gene expression profiling in the clinical management of ovarian cancer. European journal of cancer 42, 2930-8 (2006)PMID:17055255 97. Ruijs, M.W., Verhoef, S., Wigbout, G., Pruntel, R., Floore, A.N., de Jong, D., van ‘t Veer, L.J. & Menko, F.H. Late-onset common cancers in a kindred with an Arg213Gln TP53 germline mutation. Fam Cancer 5, 169-74 (2006)PMID:16736287 98. van Houwelingen, H.C., Bruinsma, T., Hart, A.A., van ‘t Veer, L.J. & Wessels, L.F. Cross-validated Cox regression on microarray gene expression data. Statistics in medicine 25, 3201-16 (2006)PMID:16143967 99. Ach, R.A., Floore, A., Curry, B., Lazar, V., Glas, A.M., Pover, R., Tsalenko, A., Ripoche, H., Cardoso, F., d'Assignies, M.S., Bruhn, L. & van ‘t Veer, L.J. Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnostic tools. BMC Genomics 8(2007) 100. Broeks, A., Braaf, L.M., Huseinovic, A., Nooijen, A., Urbanus, J., Hogervorst, F.B.L., Schmidt, M.K., Klijn, J.G.M., Russell, N.S., Van Leeuwen, F.E. & van ‘t Veer, L.J. Identification of women with an increased risk of developing radiation-induced breast cancer: A case only study. Breast Cancer Research 9(2007) 101. Bueno-de-Mesquita, J.M., van Harten, W.H., Retel, V.P., van ‘t Veer, L.J., van Dam, F.S., Karsenberg, K., Douma, K.F., van Tinteren, H., Peterse, J.L., Wesseling, J., Wu, T.S., Atsma, D., Rutgers, E.J., Brink, G., Floore, A.N., Glas, A.M., Roumen, R.M., Bellot, F.E., van Krimpen, C., Rodenhuis, S., van de Vijver, M.J. & Linn, S.C. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncology 8, 1079-1087 (2007) 102. Cardoso, F., Piccart-Gebhart, M., van ‘t Veer, L.J. & Rutgers, E. The MINDACT trial: the first prospective clinical validation of a genomic tool. Molecular oncology 1, 246-51 (2007)PMID:19383299 103. Cox, A., Dunning, A.M., Garcia-Closas, M., Balasubramanian, S., Reed, M.W.R., Pooley, K.A., Scollen, S., Baynes, C., Ponder, B.A.J., Chanock, S., Lissowska, J., Brinton, L., Peplonska, B., Southey, M.C., Hopper, J.L., McCredie, M.R.E., Giles, G.G., Fletcher, O., Johnson, N., Dos Santos Silva, I., Gibson, L., Bojesen, S.E., Nordestgaard, B.G., Axelsson, C.K., Torres, D., Hamann, U., Justenhoven, C., Brauch, H., Chang-Claude, J., Kropp, S., Risch, A., Wang-Gohrke, S., Schürmann, P., Bogdanova, N., Dörk, T., Fagerholm, R., Aaltonen, K., Blomqvist, C., Nevanlinna, H., Seal, S., Renwick, A., Stratton, M.R., Rahman, N., Sangrajrang, S., Hughes, D., Odefrey, F., Brennan, P., Spurdle, A.B., Chenevix-Trench, G., Beesley, J., Mannermaa, A., Hartikainen, J., Kataja, V., Kosma, V.M., Couch, F.J., Olson, J.E., Goode, E.L., Broeks, A., Schmidt, M.K., Hogervorst, F.B.L., van ‘t Veer, L.J., Kang, D., Yoo, K.Y., Noh, D.Y., Ahn, S.H., Wedrén, S., Hall, P., Low, Y.L., Liu, J., Milne, R.L., Ribas, G., Gonzalez-Neira, A., Benitez, J., Sigurdson, A.J., Stredrick, D.L., Alexander, B.H., Struewing, J.P., Pharoah, P.D.P. & Easton, D.F. A common coding variant in CASP8 is associated with breast cancer risk. Nature Genetics 39, 352-358 (2007) 104. Glas, A.M., Knoops, L., Delahaye, L., Kersten, M.J., Kibbelaar, R.E., Wessels, L.A., van Laar, R., van Krieken, J.H., Baars, J.W., Raemaekers, J., Kluin, P.M., van ‘t Veer, L.J. & de Jong, D. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 25, 390-8 (2007)PMID:17200149 105. Knoops, L., Haas, R., de Kemp, S., Majoor, D., Broeks, A., Eldering, E., de Boer, J.P., Verheij, M., van Ostrom, C., de Vries, A., van ‘t Veer, L.J. & de Jong, D. In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma. Blood 110, 1116-22 (2007)PMID:17483295 106. Mook, S., van ‘t Veer, L.J., Rutgers, E.J.T., Piccart-Gebhart, M.J. & Cardoso, F. Individualization of therapy using mammaprint®™: From development to the MINDACT trial. Cancer Genomics and Proteomics 4, 147-156 (2007) 107. Ruijs, M.W.G., Schmidt, M.K., Nevanlinna, H., Tommiska, J., Aittomäki, K., Pruntel, R., Verhoef, S. & van ‘t Veer, L.J. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. European Journal of Human Genetics 15, 110-114 (2007) 108. Schmidt, M.K., Reincke, S., Broeks, A., Braaf, L.M., Hogervorst, F.B., Tollenaar, R.A., Johnson, N., Fletcher, O., Peto, J., Tommiska, J., Blomqvist, C., Nevanlinna, H.A., Healey, C.S., Dunning, A.M., Pharoah, P.D., Easton, D.F., Dork, T. & van ‘t Veer, L.J. Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer research 67, 9584-90 (2007)PMID:17909070 109. Schmidt, M.K., Tollenaar, R.A.E.M., De Kemp, S.R., Broeks, A., Cornelisse, C.J., Smit, V.T.H.B.M., Peterse, J.L., Van Leeuwen, F.E. & van ‘t Veer, L.J. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. Journal of Clinical Oncology 25, 64-69 (2007) Page 21 of 38 Laura J. van ‘t Veer – CV 110. van Hest, L.P., Ruijs, M.W., Wagner, A., van der Meer, C.A., Verhoef, S., van ‘t Veer, L.J. & Meijers-Heijboer, H. Two TP53 germline mutations in a classical Li-Fraumeni syndrome family. Familial cancer 6, 311-6 (2007)PMID:17318340 111. Vrieling, A., Rookus, M.A., Kampman, E., Bonfrer, J.M., Korse, C.M., van Doorn, J., Lampe, J.W., Cats, A., Witteman, B.J., van Leeuwen, F.E., van ‘t Veer, L.J. & Voskuil, D.W. Isolated isoflavones do not affect the circulating insulin-like growth factor system in men at increased colorectal cancer risk. The Journal of nutrition 137, 379-83 (2007)PMID:17237315 112. Vrieling, A., Voskuil, D.W., Bonfrer, J.M., Korse, C.M., van Doorn, J., Cats, A., Depla, A.C., Timmer, R., Witteman, B.J., van Leeuwen, F.E., van ‘t Veer, L.J., Rookus, M.A. & Kampman, E. Lycopene supplementation elevates circulating insulinlike growth factor binding protein-1 and -2 concentrations in persons at greater risk of colorectal cancer. The American journal of clinical nutrition 86, 1456-62 (2007)PMID:17991659 113. Atwal, G.S., Rabadan, R., Lozano, G., Strong, L.C., Ruijs, M.W., Schmidt, M.K., van ‘t Veer, L.J., Nevanlinna, H., Tommiska, J., Aittomaki, K., Bougeard, G., Frebourg, T., Levine, A.J. & Bond, G.L. An information-theoretic analysis of genetics, gender and age in cancer patients. PloS one 3, e1951 (2008).PMC:2276689 PMID:18398474 114. Bridgewater, J., van Laar, R., Floore, A. & Van, T.V.L. Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. British journal of cancer 98, 1425-30 (2008).PMC:2361712 PMID:18414470 115. Broeks, A., Braaf, L.M., Huseinovic, A., Schmidt, M.K., Russell, N.S., van Leeuwen, F.E., Hogervorst, F.B. & van ‘t Veer, L.J. The spectrum of ATM missense variants and their contribution to contralateral breast cancer. Breast Cancer Res Treat 107, 243-8 (2008).PMC:2137941 PMID:17393301 116. Cardoso, F., van ‘t Veer, L.J., Rutgers, E., Loi, S., Mook, S. & Piccart-Gebhart, M.J. Clinical application of the 70-gene profile: The MINDACT trial. Journal of Clinical Oncology 26, 729-735 (2008) 117. Cleton-Jansen, A.M., van Eijk, R., Lombaerts, M., Schmidt, M.K., van ‘t Veer, L.J., Philippo, K., Zimmerman, R.M., Peterse, J.L., Smit, V.T., van Wezel, T. & Cornelisse, C.J. ATBF1 and NQO1 as candidate targets for allelic loss at chromosome arm 16q in breast cancer: absence of somatic ATBF1 mutations and no role for the C609T NQO1 polymorphism. BMC cancer 8, 105 (2008).PMC:2377272 PMID:18416817 118. Haibe-Kains, B., Desmedt, C., Piette, F., Buyse, M., Cardoso, F., van ‘t Veer, L.J., Piccart, M., Bontempi, G. & Sotiriou, C. Comparison of prognostic gene expression signatures for breast cancer. BMC genomics 9, 394 (2008).PMC:2533026 PMID:18717985 119. Horlings, H.M., van Laar, R.K., Kerst, J.M., Helgason, H.H., Wesseling, J., van der Hoeven, J.J., Warmoes, M.O., Floore, A., Witteveen, A., Lahti-Domenici, J., Glas, A.M., van ‘t Veer, L.J. & de Jong, D. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26, 4435-41 (2008)PMID:18802156 120. Kroon, B.K., Leijte, J.A., van Boven, H., Wessels, L.F., Velds, A., Horenblas, S. & van ‘t Veer, L.J. Microarray geneexpression profiling to predict lymph node metastasis in penile carcinoma. BJU international 102, 510-5 (2008)PMID:18476970 121. Molloy, T. & van ‘t Veer, L.J. Recent advances in metastasis research. Curr Opin Genet Dev 18, 35-41 (2008)PMID:18337081 122. Molloy, T.J., Bosma, A.J. & van ‘t Veer, L.J. Towards an optimized platform for the detection, enrichment, and semiquantitation circulating tumor cells. Breast cancer research and treatment 112, 297-307 (2008)PMID:18213476 123. Reyal, F., van Vliet, M.H., Armstrong, N.J., Horlings, H.M., de Visser, K.E., Kok, M., Teschendorff, A.E., Mook, S., van ‘t Veer, L.J., Caldas, C., Salmon, R.J., van de Vijver, M.J. & Wessels, L.F. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res 10, R93 (2008).PMC:2656909 PMID:19014521 124. van ‘t Veer, L.J. & Bernards, R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452, 564-70 (2008)PMID:18385730 125. Voskuil, D.W., Vrieling, A., Korse, C.M., Beijnen, J.H., Bonfrer, J.M., van Doorn, J., Kaas, R., Oldenburg, H.S., Russell, N.S., Rutgers, E.J., Verhoef, S., van Leeuwen, F.E., van ‘t Veer, L.J. & Rookus, M.A. Effects of lycopene on the insulinlike growth factor (IGF) system in premenopausal breast cancer survivors and women at high familial breast cancer risk. Nutrition and cancer 60, 342-53 (2008)PMID:18444168 126. Vrieling, A., Rookus, M.A., Kampman, E., Bonfrer, J.M., Bosma, A., Cats, A., van Doorn, J., Korse, C.M., Witteman, B.J., van Leeuwen, F.E., van ‘t Veer, L.J. & Voskuil, D.W. No effect of red clover-derived isoflavone intervention on the insulinlike growth factor system in women at increased risk of colorectal cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 17, 2585-93 (2008)PMID:18842999 127. Weigelt, B., Horlings, H.M., Kreike, B., Hayes, M.M., Hauptmann, M., Wessels, L.F., de Jong, D., Van de Vijver, M.J., van ‘t Veer, L.J. & Peterse, J.L. Refinement of breast cancer classification by molecular characterization of histological special types. The Journal of pathology 216, 141-50 (2008)PMID:18720457 128. Wittner, B.S., Sgroi, D.C., Ryan, P.D., Bruinsma, T.J., Glas, A.M., Male, A., Dahiya, S., Habin, K., Bernards, R., Haber, D.A., van ‘t Veer, L.J. & Ramaswamy, S. Analysis of the MammaPrint breast cancer assay in a predominantly Page 22 of 38 Laura J. van ‘t Veer – CV 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. postmenopausal cohort. Clinical cancer research : an official journal of the American Association for Cancer Research 14, 2988-93 (2008).PMC:3089800 PMID:18483364 Albain, K.S., Paik, S. & van ‘t Veer, L.J. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast 18 Suppl 3, S141-5 (2009)PMID:19914534 Bueno-de-Mesquita, J.M., Linn, S.C., Keijzer, R., Wesseling, J., Nuyten, D.S., van Krimpen, C., Meijers, C., de Graaf, P.W., Bos, M.M., Hart, A.A., Rutgers, E.J., Peterse, J.L., Halfwerk, H., de Groot, R., Pronk, A., Floore, A.N., Glas, A.M., van ‘t Veer, L.J. & van de Vijver, M.J. Validation of 70-gene prognosis signature in node-negative breast cancer. Breast cancer research and treatment 117, 483-95 (2009)PMID:18819002 Fletcher, O., Johnson, N., Dos Santos Silva, I., Kilpivaara, O., Aittomaki, K., Blomqvist, C., Nevanlinna, H., Wasielewski, M., Meijers-Heijerboer, H., Broeks, A., Schmidt, M.K., van ‘t Veer, L.J., Bremer, M., Dork, T., Chekmariova, E.V., Sokolenko, A.P., Imyanitov, E.N., Hamann, U., Rashid, M.U., Brauch, H., Justenhoven, C., Ashworth, A. & Peto, J. Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 18, 230-4 (2009).PMC:2727696 PMID:19124502 Gaudet, M.M., Milne, R.L., Cox, A., Camp, N.J., Goode, E.L., Humphreys, M.K., Dunning, A.M., Morrison, J., Giles, G.G., Severi, G., Baglietto, L., English, D.R., Couch, F.J., Olson, J.E., Wang, X., Chang-Claude, J., Flesch-Janys, D., Abbas, S., Salazar, R., Mannermaa, A., Kataja, V., Kosma, V.M., Lindblom, A., Margolin, S., Heikkinen, T., Kampjarvi, K., Aaltonen, K., Nevanlinna, H., Bogdanova, N., Coinac, I., Schurmann, P., Dork, T., Bartram, C.R., Schmutzler, R.K., Tchatchou, S., Burwinkel, B., Brauch, H., Torres, D., Hamann, U., Justenhoven, C., Ribas, G., Arias, J.I., Benitez, J., Bojesen, S.E., Nordestgaard, B.G., Flyger, H.L., Peto, J., Fletcher, O., Johnson, N., Dos Santos Silva, I., Fasching, P.A., Beckmann, M.W., Strick, R., Ekici, A.B., Broeks, A., Schmidt, M.K., van Leeuwen, F.E., van ‘t Veer, L.J., Southey, M.C., Hopper, J.L., Apicella, C., Haiman, C.A., Henderson, B.E., Le Marchand, L., Kolonel, L.N., Kristensen, V., Grenaker Alnaes, G., Hunter, D.J., Kraft, P., Cox, D.G., Hankinson, S.E., Seynaeve, C., Vreeswijk, M.P., Tollenaar, R.A., Devilee, P., Chanock, S., Lissowska, J., Brinton, L., Peplonska, B., Czene, K., Hall, P., Li, Y., Liu, J., Balasubramanian, S., Rafii, S., Reed, M.W., Pooley, K.A., Conroy, D., Baynes, C., Kang, D., Yoo, K.Y., Noh, D.Y., Ahn, S.H., Shen, C.Y., Wang, H.C., Yu, J.C., Wu, P.E., Anton-Culver, H., Ziogoas, A., Egan, K., Newcomb, P., Titus-Ernstoff, L., Trentham Dietz, A., Sigurdson, A.J., Alexander, B.H., Bhatti, P., Allen-Brady, K., Cannon-Albright, L.A., Wong, J., Chenevix-Trench, G., Spurdle, A.B., Beesley, J., Pharoah, P.D., Easton, D.F. & Garcia-Closas, M. Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 18, 1610-6 (2009).PMC:2737177 PMID:19423537 He, Y., van ‘t Veer, L.J., Mikolajewska-Hanclich, I., van Velthuysen, M.L., Zeestraten, E.C., Nagtegaal, I.D., van de Velde, C.J. & Marijnen, C.A. PIK3CA mutations predict local recurrences in rectal cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research 15, 6956-62 (2009)PMID:19903786 Knauer, M., Wenzl, E., Rutgers, E.J.T., Linn, S.C. & van ‘t Veer, L.J. Gene expression profiling in breast cancer - Design of a pooled database to address open questions. European Surgery - Acta Chirurgica Austriaca 41, 221-227 (2009) Kok, M., Koornstra, R.H., Margarido, T.C., Fles, R., Armstrong, N.J., Linn, S.C., van ‘t Veer, L.J. & Weigelt, B. Mammosphere-derived gene set predicts outcome in patients with ER-positive breast cancer. The Journal of pathology 218, 316-26 (2009)PMID:19353633 Kok, M., Linn, S.C., Van Laar, R.K., Jansen, M.P.H.M., Van Den Berg, T.M., Delahaye, L.J.M.J., Glas, A.M., Peterse, J.L., Hauptmann, M., Foekens, J.A., Klijn, J.G.M., Wessels, L.F.A., van ‘t Veer, L.J. & Berns, E.M.J.J. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. Breast Cancer Research and Treatment 113, 275-283 (2009) Linn, S.C. & van ‘t Veer, L.J. Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept. Eur J Cancer 45 Suppl 1, 11-26 (2009)PMID:19775601 Mook, S., Bonnefoi, H., Pruneri, G., Larsimont, D., Jaskiewicz, J., Sabadell, M.D., MacGrogan, G., van ‘t Veer, L.J., Cardoso, F. & Rutgers, E.J. Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial. European Journal of Cancer 45, 1201-1208 (2009) Mook, S., Schmidt, M.K., Rutgers, E.J., van de Velde, A.O., Visser, O., Rutgers, S.M., Armstrong, N., van ‘t Veer, L.J. & Ravdin, P.M. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. The lancet oncology 10, 1070-6 (2009)PMID:19801202 Mook, S., Schmidt, M.K., Viale, G., Pruneri, G., Eekhout, I., Floore, A., Glas, A.M., Bogaerts, J., Cardoso, F., PiccartGebhart, M.J., Rutgers, E.T. & van ‘t Veer, L.J. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Research and Treatment 116, 295302 (2009) Noordzij, J.G., Wulffraat, N.M., Haraldsson, A., Meyts, I., van ‘t Veer, L.J., Hogervorst, F.B., Warris, A. & Weemaes, C.M. Ataxia-telangiectasia patients presenting with hyper-IgM syndrome. Archives of disease in childhood 94, 448-9 (2009)PMID:19224889 Page 23 of 38 Laura J. van ‘t Veer – CV 142. Ruijs, M.W., Broeks, A., Menko, F.H., Ausems, M.G., Wagner, A., Oldenburg, R., Meijers-Heijboer, H., van ‘t Veer, L.J. & Verhoef, S. The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype. Hereditary cancer in clinical practice 7, 4 (2009).PMC:2664322 PMID:19338683 143. Schmidt, M.K., Tommiska, J., Broeks, A., van Leeuwen, F.E., van ‘t Veer, L.J., Pharoah, P.D., Easton, D.F., Shah, M., Humphreys, M., Dork, T., Reincke, S.A., Fagerholm, R., Blomqvist, C. & Nevanlinna, H. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. Breast cancer research : BCR 11, R89 (2009).PMC:2815553 PMID:20021639 144. Schmidt, M.K., Vermeulen, E., Tollenaar, R.A.E.M., van ‘t Veer, L.J. & Leeuwen, F.E.v. Regulatory aspects of genetic research with residual human tissue: Effective and efficient data coding. European Journal of Cancer 45, 2376-2382 (2009) 145. Stephens, P.J., McBride, D.J., Lin, M.L., Varela, I., Pleasance, E.D., Simpson, J.T., Stebbings, L.A., Leroy, C., Edkins, S., Mudie, L.J., Greenman, C.D., Jia, M., Latimer, C., Teague, J.W., Lau, K.W., Burton, J., Quail, M.A., Swerdlow, H., Churcher, C., Natrajan, R., Sieuwerts, A.M., Martens, J.W., Silver, D.P., Langerod, A., Russnes, H.E., Foekens, J.A., ReisFilho, J.S., van ‘t Veer, L.J., Richardson, A.L., Borresen-Dale, A.L., Campbell, P.J., Futreal, P.A. & Stratton, M.R. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462, 1005-10 (2009)PMID:20033038 146. van Laar, R.K., Ma, X.J., de Jong, D., Wehkamp, D., Floore, A.N., Warmoes, M.O., Simon, I., Wang, W., Erlander, M., van ‘t Veer, L.J. & Glas, A.M. Implementation of a novel microarray-based diagnostic test for cancer of unknown primary. International journal of cancer. Journal international du cancer 125, 1390-7 (2009)PMID:19536816 147. Verhagen, M.M., Abdo, W.F., Willemsen, M.A., Hogervorst, F.B., Smeets, D.F., Hiel, J.A., Brunt, E.R., van Rijn, M.A., Majoor Krakauer, D., Oldenburg, R.A., Broeks, A., Last, J.I., van ‘t Veer, L.J., Tijssen, M.A., Dubois, A.M., Kremer, H.P., Weemaes, C.M., Taylor, A.M. & van Deuren, M. Clinical spectrum of ataxia-telangiectasia in adulthood. Neurology 73, 4307 (2009)PMID:19535770 148. Vrieling, A., Voskuil, D.W., Bosma, A., Majoor, D.M., van Doorn, J., Cats, A., Depla, A.C., Timmer, R., Witteman, B.J., Wesseling, J., Kampman, E. & van ‘t Veer, L.J. Expression of insulin-like growth factor system components in colorectal tissue and its relation with serum IGF levels. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 19, 126-35 (2009)PMID:18801683 149. Broeks, A., Braaf, L.M., Wessels, L.F., van de Vijver, M., De Bruin, M.L., Stovall, M., Russell, N.S., van Leeuwen, F.E. & van ‘t Veer, L.J. Radiation-associated breast tumors display a distinct gene expression profile. Int J Radiat Oncol Biol Phys 76, 540-7 (2010)PMID:20117289 150. Bruin, S.C., Klijn, C., Liefers, G.J., Braaf, L.M., Joosse, S.A., van Beers, E.H., Verwaal, V.J., Morreau, H., Wessels, L.F., van Velthuysen, M.L., Tollenaar, R.A. & van ‘t Veer, L.J. Specific genomic aberrations in primary colorectal cancer are associated with liver metastases. BMC Cancer 10, 662 (2010)PMID:21126340 151. Bruin, S.C., Verwaal, V.J., Vincent, A., van ‘t Veer, L.J. & van Velthuysen, M.L. A clinicopathologic analysis of peritoneal metastases of colorectal and appendiceal origin. Annals of surgical oncology 17, 2330-40 (2010)PMID:20232161 152. de Graauw, M., van Miltenburg, M.H., Schmidt, M.K., Pont, C., Lalai, R., Kartopawiro, J., Pardali, E., Le Devedec, S.E., Smit, V.T., van der Wal, A., van ‘t Veer, L.J., Cleton-Jansen, A.M., ten Dijke, P. & van de Water, B. Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells. Proc Natl Acad Sci U S A 107, 6340-5 (2010).PMC:2852023 PMID:20308542 153. Fletcher, O., Johnson, N., dos Santos Silva, I., Orr, N., Ashworth, A., Nevanlinna, H., Heikkinen, T., Aittomaki, K., Blomqvist, C., Burwinkel, B., Bartram, C.R., Meindl, A., Schmutzler, R.K., Cox, A., Brock, I., Elliott, G., Reed, M.W., Southey, M.C., Smith, L., Spurdle, A.B., Hopper, J.L., Couch, F.J., Olson, J.E., Wang, X., Fredericksen, Z., Schurmann, P., Waltes, R., Bremer, M., Dork, T., Devilee, P., van Asperen, C.J., Tollenaar, R.A., Seynaeve, C., Hall, P., Czene, K., Humphreys, K., Liu, J., Ahmed, S., Dunning, A.M., Maranian, M., Pharoah, P.D., Chenevix-Trench, G., Beesley, J., Bogdanova, N.V., Antonenkova, N.N., Zalutsky, I.V., Anton-Culver, H., Ziogas, A., Brauch, H., Ko, Y.D., Hamann, U., Fasching, P.A., Strick, R., Ekici, A.B., Beckmann, M.W., Giles, G.G., Severi, G., Baglietto, L., English, D.R., Milne, R.L., Benitez, J., Arias, J.I., Pita, G., Nordestgaard, B.G., Bojesen, S.E., Flyger, H., Kang, D., Yoo, K.Y., Noh, D.Y., Mannermaa, A., Kataja, V., Kosma, V.M., Garcia-Closas, M., Chanock, S., Lissowska, J., Brinton, L.A., Chang-Claude, J., Wang-Gohrke, S., Broeks, A., Schmidt, M.K., van Leeuwen, F.E., van ‘t Veer, L.J., Margolin, S., Lindblom, A., Humphreys, M.K., Morrison, J., Platte, R., Easton, D.F. & Peto, J. Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 19, 2143-51 (2010).PMC:2938473 PMID:20826828 154. Gaudet, M.M., Kirchhoff, T., Green, T., Vijai, J., Korn, J.M., Guiducci, C., Segre, A.V., McGee, K., McGuffog, L., Kartsonaki, C., Morrison, J., Healey, S., Sinilnikova, O.M., Stoppa-Lyonnet, D., Mazoyer, S., Gauthier-Villars, M., Sobol, H., Longy, M., Frenay, M., Collaborators, G.S., Hogervorst, F.B., Rookus, M.A., Collee, J.M., Hoogerbrugge, N., van Roozendaal, K.E., Piedmonte, M., Rubinstein, W., Nerenstone, S., Van Le, L., Blank, S.V., Caldes, T., de la Hoya, M., Nevanlinna, H., Aittomaki, K., Lazaro, C., Blanco, I., Arason, A., Johannsson, O.T., Barkardottir, R.B., Devilee, P., Olopade, O.I., Neuhausen, S.L., Wang, X., Fredericksen, Z.S., Peterlongo, P., Manoukian, S., Barile, M., Viel, A., Radice, P., Phelan, C.M., Narod, S., Rennert, G., Lejbkowicz, F., Flugelman, A., Andrulis, I.L., Glendon, G., Ozcelik, H., Toland, A.E., Page 24 of 38 Laura J. van ‘t Veer – CV 155. 156. 157. 158. Montagna, M., D'Andrea, E., Friedman, E., Laitman, Y., Borg, A., Beattie, M., Ramus, S.J., Domchek, S.M., Nathanson, K.L., Rebbeck, T., Spurdle, A.B., Chen, X., Holland, H., John, E.M., Hopper, J.L., Buys, S.S., Daly, M.B., Southey, M.C., Terry, M.B., Tung, N., Overeem Hansen, T.V., Nielsen, F.C., Greene, M.I., Mai, P.L., Osorio, A., Duran, M., Andres, R., Benitez, J., Weitzel, J.N., Garber, J., Hamann, U., Peock, S., Cook, M., Oliver, C., Frost, D., Platte, R., Evans, D.G., Lalloo, F., Eeles, R., Izatt, L., Walker, L., Eason, J., Barwell, J., Godwin, A.K., Schmutzler, R.K., Wappenschmidt, B., Engert, S., Arnold, N., Gadzicki, D., Dean, M., Gold, B., Klein, R.J., Couch, F.J., Chenevix-Trench, G., Easton, D.F., Daly, M.J., Antoniou, A.C., Altshuler, D.M., Offit, K., Sinilnikova, O., Barjhoux, L., Giraud, S., Leone, M., Houdayer, C., Moncoutier, V., Belotti, M., de Pauw, A., Bressac-de-Paillerets, B., Remenieras, A., Byrde, V., Caron, O., Lenoir, G., Bignon, Y.J., Uhrhammer, N., Lasset, C., Bonadona, V., Hardouin, A., Berthet, P., Bourdon, V., Noguchi, T., Eisinger, F., Coulet, F., Colas, C., Soubrier, F., Coupier, I., Peyrat, J.P., Fournier, J., Revillion, F., Vennin, P., Adenis, C., Rouleau, E., Lidereau, R., Demange, L., Nogues, C., Muller, D., Fricker, J.P., Sevenet, N., Toulas, C., Guimbaud, R., Gladieff, L., Feillel, V., Leroux, D., Dreyfus, H., Rebischung, C., Cassini, C., Faivre, L., Prieur, F., Ferrer, S.F., Venat-Bouvet, L., Lynch, H.T., Verhoef, S., Verheus, M., van ‘t Veer, L.J., van Leeuwen, F.E., Collee, M., van den Ouweland, A.M., Jager, A., Hooning, M.J., TilanusLinthorst, M.M., Seynaeve, C., van Asperen, C.J., Wijnen, J.T., Vreeswijk, M.P., Tollenaar, R.A., Ligtenberg, M.J., Ausems, M.G., van der Luijt, R.B., Aalfs, C.M., van Os, T.A., Gille, J.J., Waisfisz, Q., Meijers-Heijboer, H., Gomez-Garcia, E.B., van Roozendaal, C.E., Blok, M.J., Oosterwijk, J.C., van der Hout, A.H., Mourits, M.J. & Vasen, H.F. Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet 6, e1001183 (2010).PMC:2965747 PMID:21060860 He, Y., van ‘t Veer, L.J., Lopez-Yurda, M., van de Velde, C.J. & Marijnen, C.A. Do rectal cancer patients with PIK3CA mutations benefit from preoperative radiotherapy with regard to local recurrences? Clin Cancer Res 16, 6179 (2010)PMID:21169263 Hudson, T.J., Anderson, W., Artez, A., Barker, A.D., Bell, C., Bernabe, R.R., Bhan, M.K., Calvo, F., Eerola, I., Gerhard, D.S., Guttmacher, A., Guyer, M., Hemsley, F.M., Jennings, J.L., Kerr, D., Klatt, P., Kolar, P., Kusada, J., Lane, D.P., Laplace, F., Youyong, L., Nettekoven, G., Ozenberger, B., Peterson, J., Rao, T.S., Remacle, J., Schafer, A.J., Shibata, T., Stratton, M.R., Vockley, J.G., Watanabe, K., Yang, H., Yuen, M.M., Knoppers, B.M., Bobrow, M., Cambon-Thomsen, A., Dressler, L.G., Dyke, S.O., Joly, Y., Kato, K., Kennedy, K.L., Nicolas, P., Parker, M.J., Rial-Sebbag, E., Romeo-Casabona, C.M., Shaw, K.M., Wallace, S., Wiesner, G.L., Zeps, N., Lichter, P., Biankin, A.V., Chabannon, C., Chin, L., Clement, B., de Alava, E., Degos, F., Ferguson, M.L., Geary, P., Hayes, D.N., Johns, A.L., Kasprzyk, A., Nakagawa, H., Penny, R., Piris, M.A., Sarin, R., Scarpa, A., van de Vijver, M., Futreal, P.A., Aburatani, H., Bayes, M., Botwell, D.D., Campbell, P.J., Estivill, X., Grimmond, S.M., Gut, I., Hirst, M., Lopez-Otin, C., Majumder, P., Marra, M., McPherson, J.D., Ning, Z., Puente, X.S., Ruan, Y., Stunnenberg, H.G., Swerdlow, H., Velculescu, V.E., Wilson, R.K., Xue, H.H., Yang, L., Spellman, P.T., Bader, G.D., Boutros, P.C., Flicek, P., Getz, G., Guigo, R., Guo, G., Haussler, D., Heath, S., Hubbard, T.J., Jiang, T., Jones, S.M., Li, Q., Lopez-Bigas, N., Luo, R., Muthuswamy, L., Ouellette, B.F., Pearson, J.V., Quesada, V., Raphael, B.J., Sander, C., Speed, T.P., Stein, L.D., Stuart, J.M., Teague, J.W., Totoki, Y., Tsunoda, T., Valencia, A., Wheeler, D.A., Wu, H., Zhao, S., Zhou, G., Lathrop, M., Thomas, G., Yoshida, T., Axton, M., Gunter, C., Miller, L.J., Zhang, J., Haider, S.A., Wang, J., Yung, C.K., Cross, A., Liang, Y., Gnaneshan, S., Guberman, J., Hsu, J., Chalmers, D.R., Hasel, K.W., Kaan, T.S., Lowrance, W.W., Masui, T., Rodriguez, L.L., Vergely, C., Bowtell, D.D., Cloonan, N., deFazio, A., Eshleman, J.R., Etemadmoghadam, D., Gardiner, B.A., Kench, J.G., Sutherland, R.L., Tempero, M.A., Waddell, N.J., Wilson, P.J., Gallinger, S., Tsao, M.S., Shaw, P.A., Petersen, G.M., Mukhopadhyay, D., DePinho, R.A., Thayer, S., Shazand, K., Beck, T., Sam, M., Timms, L., Ballin, V., Lu, Y., Ji, J., Zhang, X., Chen, F., Hu, X., Yang, Q., Tian, G., Zhang, L., Xing, X., Li, X., Zhu, Z., Yu, Y., Yu, J., Tost, J., Brennan, P., Holcatova, I., Zaridze, D., Brazma, A., Egevard, L., Prokhortchouk, E., Banks, R.E., Uhlen, M., Viksna, J., Ponten, F., Skryabin, K., Birney, E., Borg, A., Borresen-Dale, A.L., Caldas, C., Foekens, J.A., Martin, S., Reis-Filho, J.S., Richardson, A.L., Sotiriou, C., Thoms, G., van ‘t Veer, L.J., Birnbaum, D., Blanche, H., Boucher, P., Boyault, S., MassonJacquemier, J.D., Pauporte, I., Pivot, X., Vincent-Salomon, A., Tabone, E., Theillet, C., Treilleux, I., Bioulac-Sage, P., Decaens, T., Franco, D., Gut, M., Samuel, D., Zucman-Rossi, J., Eils, R., Brors, B., Korbel, J.O., Korshunov, A., Landgraf, P., Lehrach, H., Pfister, S., Radlwimmer, B., Reifenberger, G., Taylor, M.D., von Kalle, C., Majumder, P.P., Pederzoli, P., Lawlor, R.A., Delledonne, M., Bardelli, A., Gress, T., Klimstra, D., Zamboni, G., Nakamura, Y., Miyano, S., Fujimoto, A., Campo, E., de Sanjose, S., Montserrat, E., Gonzalez-Diaz, M., Jares, P., Himmelbaue, H., Bea, S., Aparicio, S., Easton, D.F., Collins, F.S., Compton, C.C., Lander, E.S., Burke, W., Green, A.R., Hamilton, S.R., Kallioniemi, O.P., Ley, T.J., Liu, E.T. & Wainwright, B.J. International network of cancer genome projects. Nature 464, 993-8 (2010).PMC:2902243 PMID:20393554 Ishitobi, M., Goranova, T.E., Komoike, Y., Motomura, K., Koyama, H., Glas, A.M., van Lienen, E., Inaji, H., van ‘t Veer, L.J. & Kato, K. Clinical utility of the 70-gene MammaPrint profile in a Japanese population. Japanese journal of clinical oncology 40, 508-12 (2010)PMID:20110242 Knauer, M., Cardoso, F., Wesseling, J., Bedard, P.L., Linn, S.C., Rutgers, E.J. & van ‘t Veer, L.J. Identification of a lowrisk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. Br J Cancer 103, 1788-93 (2010)PMID:21081926 Page 25 of 38 Laura J. van ‘t Veer – CV 159. Knauer, M., Mook, S., Rutgers, E.J., Bender, R.A., Hauptmann, M., van de Vijver, M.J., Koornstra, R.H., Bueno-deMesquita, J.M., Linn, S.C. & van ‘t Veer, L.J. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 120, 655-61 (2010)PMID:20204499 160. Mook, S., Knauer, M., Bueno-de-Mesquita, J.M., Retel, V.P., Wesseling, J., Linn, S.C., van ‘t Veer, L.J. & Rutgers, E.J. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature. Annals of surgical oncology 17, 1406-13 (2010)PMID:20094918 161. Mook, S., Schmidt, M.K., Weigelt, B., Kreike, B., Eekhout, I., van de Vijver, M.J., Glas, A.M., Floore, A., Rutgers, E.J. & van ‘t Veer, L.J. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol 21, 717-22 (2010)PMID:19825882 162. Pijpe, A., Manders, P., Brohet, R.M., Collee, J.M., Verhoef, S., Vasen, H.F., Hoogerbrugge, N., van Asperen, C.J., Dommering, C., Ausems, M.G., Aalfs, C.M., Gomez-Garcia, E.B., van ‘t Veer, L.J., van Leeuwen, F.E. & Rookus, M.A. Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers. Breast cancer research and treatment 120, 23544 (2010)PMID:19680614 163. Ruijs, M.W., Verhoef, S., Rookus, M.A., Pruntel, R., van der Hout, A.H., Hogervorst, F.B., Kluijt, I., Sijmons, R.H., Aalfs, C.M., Wagner, A., Ausems, M.G., Hoogerbrugge, N., van Asperen, C.J., Gomez Garcia, E.B., Meijers-Heijboer, H., Ten Kate, L.P., Menko, F.H. & van ‘t Veer, L.J. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet 47, 421-8 (2010)PMID:20522432 164. Straver, M.E., Glas, A.M., Hannemann, J., Wesseling, J., Van De Vijver, M.J., Rutgers, E.J.T., Vrancken Peeters, M.J.T.F.D., Van Tinteren, H., van ‘t Veer, L.J. & Rodenhuis, S. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Research and Treatment 119, 551-558 (2010) 165. Tian, S., Roepman, P., van ‘t Veer, L.J., Bernards, R., de Snoo, F. & Glas, A.M. Biological functions of the genes in the mammaprint breast cancer profile reflect the hallmarks of cancer. Biomark Insights 5, 129-38 (2010).PMC:2999994 PMID:21151591 166. Yang, X.R., Chang-Claude, J., Goode, E.L., Couch, F.J., Nevanlinna, H., Milne, R.L., Gaudet, M., Schmidt, M.K., Broeks, A., Cox, A., Fasching, P.A., Hein, R., Spurdle, A.B., Blows, F., Driver, K., Flesch-Janys, D., Heinz, J., Sinn, P., Vrieling, A., Heikkinen, T., Aittomaki, K., Heikkila, P., Blomqvist, C., Lissowska, J., Peplonska, B., Chanock, S., Figueroa, J., Brinton, L., Hall, P., Czene, K., Humphreys, K., Darabi, H., Liu, J., van ‘t Veer, L.J., van Leeuwen, F.E., Andrulis, I.L., Glendon, G., Knight, J.A., Mulligan, A.M., O'Malley, F.P., Weerasooriya, N., John, E.M., Beckmann, M.W., Hartmann, A., Weihbrecht, S.B., Wachter, D.L., Jud, S.M., Loehberg, C.R., Baglietto, L., English, D.R., Giles, G.G., McLean, C.A., Severi, G., Lambrechts, D., Vandorpe, T., Weltens, C., Paridaens, R., Smeets, A., Neven, P., Wildiers, H., Wang, X., Olson, J.E., Cafourek, V., Fredericksen, Z., Kosel, M., Vachon, C., Cramp, H.E., Connley, D., Cross, S.S., Balasubramanian, S.P., Reed, M.W., Dork, T., Bremer, M., Meyer, A., Karstens, J.H., Ay, A., Park-Simon, T.W., Hillemanns, P., Arias Perez, J.I., Rodriguez, P.M., Zamora, P., Benitez, J., Ko, Y.D., Fischer, H.P., Hamann, U., Pesch, B., Bruning, T., Justenhoven, C., Brauch, H., Eccles, D.M., Tapper, W.J., Gerty, S.M., Sawyer, E.J., Tomlinson, I.P., Jones, A., Kerin, M., Miller, N., McInerney, N., Anton-Culver, H., Ziogas, A., Shen, C.Y., Hsiung, C.N., Wu, P.E., Yang, S.L., Yu, J.C., Chen, S.T., Hsu, G.C., Haiman, C.A., Henderson, B.E., Le Marchand, L., Kolonel, L.N., Lindblom, A., Margolin, S., Jakubowska, A., Lubinski, J., Huzarski, T., Byrski, T., Gorski, B., Gronwald, J., Hooning, M.J., Hollestelle, A., van den Ouweland, A.M., Jager, A., Kriege, M., Tilanus-Linthorst, M.M., Collee, M., Wang-Gohrke, S., Pylkas, K., Jukkola-Vuorinen, A., Mononen, K., Grip, M., Hirvikoski, P., Winqvist, R., Mannermaa, A., Kosma, V.M., Kauppinen, J., Kataja, V., Auvinen, P., Soini, Y., Sironen, R., Bojesen, S.E., Dynnes Orsted, D., Kaur-Knudsen, D., Flyger, H., Nordestgaard, B.G., Holland, H., ChenevixTrench, G., Manoukian, S., Barile, M., Radice, P., Hankinson, S.E., Hunter, D.J., Tamimi, R., Sangrajrang, S., Brennan, P., McKay, J., Odefrey, F., Gaborieau, V., Devilee, P., Huijts, P.E., Tollenaar, R., Seynaeve, C., Dite, G.S., Apicella, C., Hopper, J.L., Hammet, F., Tsimiklis, H., Smith, L.D., Southey, M.C., Humphreys, M.K., Easton, D., Pharoah, P., Sherman, M.E. & Garcia-Closas, M. Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. J Natl Cancer Inst (2010)PMID:21191117 167. Berruti, A., Generali, D., Kaufmann, M., Puztai, L., Curigliano, G., Aglietta, M., Gianni, L., Miller, W.R., Untch, M., Sotiriou, C., Daidone, M., Conte, P., Kennedy, D., Damia, G., Petronini, P., Di Cosimo, S., Bruzzi, P., Dowsett, M., Desmedt, C., Mansel, R.E., Olivetti, L., Tondini, C., Sapino, A., Fenaroli, P., Tortora, G., Thorne, H., Bertolini, F., Ferrozzi, F., Danova, M., Tagliabue, E., de Azambuja, E., Makris, A., Tampellini, M., Dontu, G., van ‘t Veer, L.J., Harris, A.L., Fox, S.B., Dogliotti, L. & Bottini, A. International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). Journal of the National Cancer Institute. Monographs 2011, 147-51 (2011)PMID:22043063 168. Esserman, L.J., Berry, D.A., Cheang, M.C., Yau, C., Perou, C.M., Carey, L., Demichele, A., Gray, J.W., Conway-Dorsey, K., Lenburg, M.E., Buxton, M.B., Davis, S.E., van ‘t Veer, L.J., Hudis, C., Chin, K., Wolf, D., Krontiras, H., Montgomery, L., Tripathy, D., Lehman, C., Liu, M.C., Olopade, O.I., Rugo, H.S., Carpenter, J.T., Livasy, C., Dressler, L., Chhieng, D., Singh, B., Mies, C., Rabban, J., Chen, Y.Y., Giri, D., Au, A. & Hylton, N. Chemotherapy response and recurrence-free survival in Page 26 of 38 Laura J. van ‘t Veer – CV 169. 170. 171. 172. 173. 174. neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast cancer research and treatment (2011)PMID:22198468 Esserman, L.J., Shieh, Y., Rutgers, E.J., Knauer, M., Retel, V.P., Mook, S., Glas, A.M., Moore, D.H., Linn, S., van Leeuwen, F.E. & van ‘t Veer, L.J. Impact of mammographic screening on the detection of good and poor prognosis breast cancers. Breast cancer research and treatment 130, 725-34 (2011)PMID:21892702 Broeks, A., Schmidt, M.K., Sherman, M.E., Couch, F.J., Hopper, J.L., Dite, G.S., Apicella, C., Smith, L.D., Hammet, F., Southey, M.C., van ‘t Veer, L.J., de Groot, R., Smit, V.T., Fasching, P.A., Beckmann, M.W., Jud, S., Ekici, A.B., Hartmann, A., Hein, A., Schulz-Wendtland, R., Burwinkel, B., Marme, F., Schneeweiss, A., Sinn, H.P., Sohn, C., Tchatchou, S., Bojesen, S.E., Nordestgaard, B.G., Flyger, H., Orsted, D.D., Kaur-Knudsen, D., Milne, R.L., Perez, J.I., Zamora, P., Rodriguez, P.M., Benitez, J., Brauch, H., Justenhoven, C., Ko, Y.D., Hamann, U., Fischer, H.P., Bruning, T., Pesch, B., Chang-Claude, J., Wang-Gohrke, S., Bremer, M., Karstens, J.H., Hillemanns, P., Dork, T., Nevanlinna, H.A., Heikkinen, T., Heikkila, P., Blomqvist, C., Aittomaki, K., Aaltonen, K., Lindblom, A., Margolin, S., Mannermaa, A., Kosma, V.M., Kauppinen, J.M., Kataja, V., Auvinen, P., Eskelinen, M., Soini, Y., Chenevix-Trench, G., Spurdle, A.B., Beesley, J., Chen, X., Holland, H., Lambrechts, D., Claes, B., Vandorpe, T., Neven, P., Wildiers, H., Flesch-Janys, D., Hein, R., Loning, T., Kosel, M., Fredericksen, Z.S., Wang, X., Giles, G.G., Baglietto, L., Severi, G., McLean, C., Haiman, C.A., Henderson, B.E., Le Marchand, L., Kolonel, L.N., Alnaes, G.G., Kristensen, V., Borresen-Dale, A.L., Hunter, D.J., Hankinson, S.E., Andrulis, I.L., Mulligan, A.M., O'Malley, F.P., Devilee, P., Huijts, P.E., Tollenaar, R.A., Van Asperen, C.J., Seynaeve, C.S., Chanock, S.J., Lissowska, J., Brinton, L., Peplonska, B., Figueroa, J., Yang, X.R., Hooning, M.J., Hollestelle, A., Oldenburg, R.A., Jager, A., Kriege, M., Ozturk, B., van Leenders, G.J., Hall, P., Czene, K., Humphreys, K., Liu, J., Cox, A., Connley, D., Cramp, H.E., Cross, S.S., Balasubramanian, S.P., Reed, M.W., Dunning, A.M., Easton, D.F., Humphreys, M.K., Caldas, C., Blows, F., Driver, K., Provenzano, E., Lubinski, J., Jakubowska, A., Huzarski, T., Byrski, T., Cybulski, C., Gorski, B., Gronwald, J., Brennan, P., Sangrajrang, S., Gaborieau, V., Shen, C.Y., Hsiung, C.N., Yu, J.C., Chen, S.T., Hsu, G.C., Hou, M.F., Huang, C.S., Anton-Culver, H., Ziogas, A., Pharoah, P.D. & Garcia-Closas, M. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Human molecular genetics 20, 3289-303 (2011).PMC:3140824 PMID:21596841 Bruin, S.C., He, Y., Mikolajewska-Hanclich, I., Liefers, G.J., Klijn, C., Vincent, A., Verwaal, V.J., de Groot, K.A., Morreau, H., van Velthuysen, M.L., Tollenaar, R.A. & van 't Veer, L.J. Molecular alterations associated with liver metastases development in colorectal cancer patients. British journal of cancer 105, 281-7 (2011).PMC:3142796 PMID:21673680 Milne, R.L., Goode, E.L., Garcia-Closas, M., Couch, F.J., Severi, G., Hein, R., Fredericksen, Z., Malats, N., Zamora, M.P., Arias Perez, J.I., Benitez, J., Dork, T., Schurmann, P., Karstens, J.H., Hillemanns, P., Cox, A., Brock, I.W., Elliot, G., Cross, S.S., Seal, S., Turnbull, C., Renwick, A., Rahman, N., Shen, C.Y., Yu, J.C., Huang, C.S., Hou, M.F., Nordestgaard, B.G., Bojesen, S.E., Lanng, C., Grenaker Alnaes, G., Kristensen, V., Borrensen-Dale, A.L., Hopper, J.L., Dite, G.S., Apicella, C., Southey, M.C., Lambrechts, D., Yesilyurt, B.T., Floris, G., Leunen, K., Sangrajrang, S., Gaborieau, V., Brennan, P., McKay, J., Chang-Claude, J., Wang-Gohrke, S., Radice, P., Peterlongo, P., Manoukian, S., Barile, M., Giles, G.G., Baglietto, L., John, E.M., Miron, A., Chanock, S.J., Lissowska, J., Sherman, M.E., Figueroa, J.D., Bogdanova, N.V., Antonenkova, N.N., Zalutsky, I.V., Rogov, Y.I., Fasching, P.A., Bayer, C.M., Ekici, A.B., Beckmann, M.W., Brenner, H., Muller, H., Arndt, V., Stegmaier, C., Andrulis, I.L., Knight, J.A., Glendon, G., Mulligan, A.M., Mannermaa, A., Kataja, V., Kosma, V.M., Hartikainen, J.M., Meindl, A., Heil, J., Bartram, C.R., Schmutzler, R.K., Thomas, G.D., Hoover, R.N., Fletcher, O., Gibson, L.J., dos Santos Silva, I., Peto, J., Nickels, S., Flesch-Janys, D., Anton-Culver, H., Ziogas, A., Sawyer, E., Tomlinson, I., Kerin, M., Miller, N., Schmidt, M.K., Broeks, A., van ‘t Veer, L.J., Tollenaar, R.A., Pharoah, P.D., Dunning, A.M., Pooley, K.A., Marme, F., Schneeweiss, A., Sohn, C., Burwinkel, B., Jakubowska, A., Lubinski, J., Jaworska, K., Durda, K., Kang, D., Yoo, K.Y., Noh, D.Y., Ahn, S.H., Hunter, D.J., Hankinson, S.E., Kraft, P., Lindstrom, S., Chen, X., Beesley, J., Hamann, U., Harth, V., Justenhoven, C., Winqvist, R., Pylkas, K., Jukkola-Vuorinen, A., Grip, M., Hooning, M., Hollestelle, A., Oldenburg, R.A., Tilanus-Linthorst, M., Khusnutdinova, E., Bermisheva, M., Prokofieva, D., Farahtdinova, A., Olson, J.E., Wang, X., Humphreys, M.K., Wang, Q., Chenevix-Trench, G. & Easton, D.F. Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20, 2222-31 (2011)PMID:21795498 van Schaik, R.H., Kok, M., Sweep, F.C., van Vliet, M., van Fessem, M., Meijer-van Gelder, M.E., Seynaeve, C., Lindemans, J., Wesseling, J., van ‘t Veer, L.J., Span, P.N., van Laarhoven, H., Sleijfer, S., Foekens, J.A., Linn, S.C. & Berns, E.M. The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. Pharmacogenomics 12, 1137-46 (2011)PMID:21830868 Figueroa, J.D., Garcia-Closas, M., Humphreys, M., Platte, R., Hopper, J.L., Southey, M.C., Apicella, C., Hammet, F., Schmidt, M.K., Broeks, A., Tollenaar, R.A., van ‘t Veer, L.J., Fasching, P.A., Beckmann, M.W., Ekici, A.B., Strick, R., Peto, J., dos Santos Silva, I., Fletcher, O., Johnson, N., Sawyer, E., Tomlinson, I., Kerin, M., Burwinkel, B., Marme, F., Schneeweiss, A., Sohn, C., Bojesen, S., Flyger, H., Nordestgaard, B.G., Benitez, J., Milne, R.L., Ignacio Arias, J., Zamora, M.P., Brenner, H., Muller, H., Arndt, V., Rahman, N., Turnbull, C., Seal, S., Renwick, A., Brauch, H., Justenhoven, C., Bruning, T., Chang-Claude, J., Hein, R., Wang-Gohrke, S., Dork, T., Schurmann, P., Bremer, M., Hillemanns, P., Page 27 of 38 Laura J. van ‘t Veer – CV 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. Nevanlinna, H., Heikkinen, T., Aittomaki, K., Blomqvist, C., Bogdanova, N., Antonenkova, N., Rogov, Y.I., Karstens, J.H., Bermisheva, M., Prokofieva, D., Gantcev, S.H., Khusnutdinova, E., Lindblom, A., Margolin, S., Chenevix-Trench, G., Beesley, J., Chen, X., Mannermaa, A., Kosma, V.M., Soini, Y., Kataja, V., Lambrechts, D., Yesilyurt, B.T., Chrisiaens, M.R., Peeters, S., Radice, P., Peterlongo, P., Manoukian, S., Barile, M., Couch, F., Lee, A.M., Diasio, R., Wang, X., Giles, G.G., Severi, G., Baglietto, L., Maclean, C., Offit, K., Robson, M., Joseph, V., Gaudet, M., John, E.M., Winqvist, R., Pylkas, K., Jukkola-Vuorinen, A., Grip, M., Andrulis, I., Knight, J.A., Mulligan, A.M., O'Malley, F.P., Brinton, L.A., Sherman, M.E., Lissowska, J., Chanock, S.J., Hooning, M., Martens, J.W., van den Ouweland, A.M., Collee, J.M., Hall, P., Czene, K., Cox, A., Brock, I.W., Reed, M.W., Cross, S.S., Pharoah, P., Dunning, A.M., Kang, D., Yoo, K.Y., Noh, D.Y., Ahn, S.H., Jakubowska, A., Lubinski, J., Jaworska, K., Durda, K., Sangrajrang, S., Gaborieau, V., Brennan, P., McKay, J., Shen, C.Y., Ding, S.L., Hsu, H.M., Yu, J.C., Anton-Culver, H., Ziogas, A., Ashworth, A., Swerdlow, A., Jones, M., Orr, N., TrenthamDietz, A., Egan, K., Newcomb, P., Titus-Ernstoff, L., Easton, D. & Spurdle, A.B. Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. Human molecular genetics 20, 4693-706 (2011).PMC:3209823 PMID:21852249 Kok, M., Zwart, W., Holm, C., Fles, R., Hauptmann, M., van ‘t Veer, L.J., Wessels, L.F., Neefjes, J., Stal, O., Linn, S.C., Landberg, G. & Michalides, R. PKA-induced phosphorylation of ERalpha at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Res Treat 125, 1-12 (2011)PMID:20213082 Loi, S., Symmans, W.F., Bartlett, J.M., Fumagalli, D., van ‘t Veer, L.J., Forbes, J.F., Bedard, P., Denkert, C., Zujewski, J., Viale, G., Pusztai, L., Esserman, L.J. & Leyland-Jones, B.R. Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. Lancet Oncol (2011)PMID:21684810 Mittempergher, L., de Ronde, J.J., Nieuwland, M., Kerkhoven, R.M., Simon, I., Rutgers, E.J., Wessels, L.F. & van ‘t Veer, L.J. Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue. PLoS One 6, e17163 (2011).PMC:3037966 PMID:21347257 Mook, S., van ‘t Veer, L.J., Rutgers, E.J., Ravdin, P.M., van de Velde, A.O., van Leeuwen, F.E., Visser, O. & Schmidt, M.K. Independent Prognostic Value of Screen Detection in Invasive Breast Cancer. J Natl Cancer Inst (2011)PMID:21350218 Salazar, R., Roepman, P., Capella, G., Moreno, V., Simon, I., Dreezen, C., Lopez-Doriga, A., Santos, C., Marijnen, C., Westerga, J., Bruin, S., Kerr, D., Kuppen, P., van de Velde, C., Morreau, H., Van Velthuysen, L., Glas, A.M., van ‘t Veer, L.J. & Tollenaar, R. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 29, 17-24 (2011)PMID:21098318 Stevens, K.N., Garcia-Closas, M., Fredericksen, Z., Kosel, M., Pankratz, V.S., Hopper, J.L., Dite, G.S., Apicella, C., Southey, M.C., Schmidt, M.K., Broeks, A., van ‘t Veer, L.J., Tollenaar, R.A., Fasching, P.A., Beckmann, M.W., Hein, A., Ekici, A.B., Johnson, N., Peto, J., Dos Santos Silva, I., Gibson, L., Sawyer, E., Tomlinson, I., Kerin, M.J., Chanock, S., Lissowska, J., Hunter, D.J., Hoover, R.N., Thomas, G.D., Milne, R.L., Perez, J.A., Gonzalez-Neira, A., Benitez, J., Burwinkel, B., Meindl, A., Schmutzler, R.K., Bartrar, C.R., Hamann, U., Ko, Y.D., Bruning, T., Chang-Claude, J., Hein, R., Wang-Gohrke, S., Dork, T., Schurmann, P., Bremer, M., Hillemanns, P., Bogdanova, N., Zalutsky, J.V., Rogov, Y.I., Antonenkova, N., Lindblom, A., Margolin, S., Mannermaa, A., Kataja, V., Kosma, V.M., Hartikainen, J., Chenevix-Trench, G., Chen, X., Peterlongo, P., Bonanni, B., Bernard, L., Manoukian, S., Wang, X., Cerhan, J., Vachon, C.M., Olson, J., Giles, G.G., Baglietto, L., McLean, C.A., Severi, G., John, E.M., Miron, A., Winqvist, R., Pylkas, K., Jukkola-Vuorinen, A., Grip, M., Andrulis, I., Knight, J.A., Glendon, G., Mulligan, A.M., Cox, A., Brock, I.W., Elliott, G., Cross, S.S., Pharoah, P.P., Dunning, A.M., Pooley, K.A., Humphreys, M.K., Wang, J., Kang, D., Yoo, K.Y., Noh, D.Y., Sangrajrang, S., Gabrieau, V., Brennan, P., McKay, J., Anton-Culver, H., Ziogas, A., Couch, F.J. & Easton, D.F. Evaluation of variation in the phosphoinositide-3kinase catalytic subunit alpha oncogene and breast cancer risk. British journal of cancer 105, 1934-9 (2011).PMC:3251877 PMID:22033276 Boudreau, A., van 't Veer, L.J. & Bissell, M.J. An "elite hacker": Breast tumors exploit the normal microenvironment program to instruct their progression and biological diversity. Cell adhesion & migration 6(2012)PMID:22863741 Cardoso, F., Costa, A., Norton, L., Cameron, D., Cufer, T., Fallowfield, L., Francis, P., Gligorov, J., Kyriakides, S., Lin, N., Pagani, O., Senkus, E., Thomssen, C., Aapro, M., Bergh, J., Di Leo, A., El Saghir, N., Ganz, P.A., Gelmon, K., Goldhirsch, A., Harbeck, N., Houssami, N., Hudis, C., Kaufman, B., Leadbeater, M., Mayer, M., Rodger, A., Rugo, H., Sacchini, V., Sledge, G., van 't Veer, L.J., Viale, G., Krop, I. & Winer, E. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 21, 242-52 (2012)PMID:22425534 Daemen, A., Wolf, D.M., Korkola, J.E., Griffith, O.L., Frankum, J.R., Brough, R., Jakkula, L.R., Wang, N.J., Natrajan, R., Reis-Filho, J.S., Lord, C.J., Ashworth, A., Spellman, P.T., Gray, J.W. & Van't Veer, L.J. Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. Breast cancer research and treatment (2012)PMID:22875744 Esserman, L.J., Berry, D.A., Cheang, M.C., Yau, C., Perou, C.M., Carey, L., DeMichele, A., Gray, J.W., Conway-Dorsey, K., Lenburg, M.E., Buxton, M.B., Davis, S.E., van 't Veer, L.J., Hudis, C., Chin, K., Wolf, D., Krontiras, H., Montgomery, L., Tripathy, D., Lehman, C., Liu, M.C., Olopade, O.I., Rugo, H.S., Carpenter, J.T., Livasy, C., Dressler, L., Chhieng, D., Singh, B., Mies, C., Rabban, J., Chen, Y.Y., Giri, D., Au, A. & Hylton, N. Chemotherapy response and recurrence-free survival in Page 28 of 38 Laura J. van ‘t Veer – CV 185. 186. 187. 188. 189. 190. 191. 192. 193. neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast cancer research and treatment 132, 1049-62 (2012).PMC:3332388 PMID:22198468 Fasching, P.A., Pharoah, P.D., Cox, A., Nevanlinna, H., Bojesen, S.E., Karn, T., Broeks, A., van Leeuwen, F.E., van 't Veer, L.J., Udo, R., Dunning, A.M., Greco, D., Aittomaki, K., Blomqvist, C., Shah, M., Nordestgaard, B.G., Flyger, H., Hopper, J.L., Southey, M.C., Apicella, C., Garcia-Closas, M., Sherman, M., Lissowska, J., Seynaeve, C., Huijts, P.E., Tollenaar, R.A., Ziogas, A., Ekici, A.B., Rauh, C., Mannermaa, A., Kataja, V., Kosma, V.M., Hartikainen, J.M., Andrulis, I.L., Ozcelik, H., Mulligan, A.M., Glendon, G., Hall, P., Czene, K., Liu, J., Chang-Claude, J., Wang-Gohrke, S., Eilber, U., Nickels, S., Dork, T., Schiekel, M., Bremer, M., Park-Simon, T.W., Giles, G.G., Severi, G., Baglietto, L., Hooning, M.J., Martens, J.W., Jager, A., Kriege, M., Lindblom, A., Margolin, S., Couch, F.J., Stevens, K.N., Olson, J.E., Kosel, M., Cross, S.S., Balasubramanian, S.P., Reed, M.W., Miron, A., John, E.M., Winqvist, R., Pylkas, K., Jukkola-Vuorinen, A., Kauppila, S., Burwinkel, B., Marme, F., Schneeweiss, A., Sohn, C., Chenevix-Trench, G., Lambrechts, D., Dieudonne, A.S., Hatse, S., van Limbergen, E., Benitez, J., Milne, R.L., Zamora, M.P., Perez, J.I., Bonanni, B., Peissel, B., Loris, B., Peterlongo, P., Rajaraman, P., Schonfeld, S.J., Anton-Culver, H., Devilee, P., Beckmann, M.W., Slamon, D.J., Phillips, K.A., Figueroa, J.D., Humphreys, M.K., Easton, D.F. & Schmidt, M.K. The role of genetic breast cancer susceptibility variants as prognostic factors. Human molecular genetics 21, 3926-39 (2012).PMC:3412377 PMID:22532573 Finkelman, B.S., Rubinstein, W.S., Friedman, S., Friebel, T.M., Dubitsky, S., Schonberger, N.S., Shoretz, R., Singer, C.F., Blum, J.L., Tung, N., Olopade, O.I., Weitzel, J.N., Lynch, H.T., Snyder, C., Garber, J.E., Schildkraut, J., Daly, M.B., Isaacs, C., Pichert, G., Neuhausen, S.L., Couch, F.J., van 't Veer, L.J., Eeles, R., Bancroft, E., Evans, D.G., Ganz, P.A., Tomlinson, G.E., Narod, S.A., Matloff, E., Domchek, S. & Rebbeck, T.R. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 30, 1321-8 (2012).PMC:3341145 PMID:22430266 Hilbers, F.S., Boekel, N.B., van den Broek, A.J., van Hien, R., Cornelissen, S., Aleman, B.M., van 't Veer, L.J., van Leeuwen, F.E. & Schmidt, M.K. Genetic variants in TGFbeta-1 and PAI-1 as possible risk factors for cardiovascular disease after radiotherapy for breast cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 102, 115-21 (2012)PMID:22100658 Kirchhoff, T., Gaudet, M.M., Antoniou, A.C., McGuffog, L., Humphreys, M.K., Dunning, A.M., Bojesen, S.E., Nordestgaard, B.G., Flyger, H., Kang, D., Yoo, K.Y., Noh, D.Y., Ahn, S.H., Dork, T., Schurmann, P., Karstens, J.H., Hillemanns, P., Couch, F.J., Olson, J., Vachon, C., Wang, X., Cox, A., Brock, I., Elliott, G., Reed, M.W., Burwinkel, B., Meindl, A., Brauch, H., Hamann, U., Ko, Y.D., Broeks, A., Schmidt, M.K., van ‘t Veer, L.J., Braaf, L.M., Johnson, N., Fletcher, O., Gibson, L., Peto, J., Turnbull, C., Seal, S., Renwick, A., Rahman, N., Wu, P.E., Yu, J.C., Hsiung, C.N., Shen, C.Y., Southey, M.C., Hopper, J.L., Hammet, F., Van Dorpe, T., Dieudonne, A.S., Hatse, S., Lambrechts, D., Andrulis, I.L., Bogdanova, N., Antonenkova, N., Rogov, J.I., Prokofieva, D., Bermisheva, M., Khusnutdinova, E., van Asperen, C.J., Tollenaar, R.A., Hooning, M.J., Devilee, P., Margolin, S., Lindblom, A., Milne, R.L., Arias, J.I., Zamora, M.P., Benitez, J., Severi, G., Baglietto, L., Giles, G.G., Kconfab, Group, A.S., Spurdle, A.B., Beesley, J., Chen, X., Holland, H., Healey, S., Wang-Gohrke, S., Chang-Claude, J., Mannermaa, A., Kosma, V.M., Kauppinen, J., Kataja, V., Agnarsson, B.A., Caligo, M.A., Godwin, A.K., Nevanlinna, H., Heikkinen, T., Fredericksen, Z., Lindor, N., Nathanson, K.L., Domchek, S.M., Swe, B., Loman, N., Karlsson, P., Askmalm, M.S., Melin, B., von Wachenfeldt, A., Hebon, Hogervorst, F.B., Verheus, M., Rookus, M.A., Seynaeve, C., Oldenburg, R.A., Ligtenberg, M.J., Ausems, M.G., Aalfs, C.M., Gille, H.J., Wijnen, J.T., Gomez Garcia, E.B., Embrace, Peock, S., Cook, M., Oliver, C.T., Frost, D., Luccarini, C., Pichert, G., Davidson, R., Chu, C., Eccles, D., Ong, K.R., Cook, J., Douglas, F., Hodgson, S., Evans, D.G., Eeles, R., Gold, B., Pharoah, P.D., Offit, K., Chenevix-Trench, G. & Easton, D.F. Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PloS one 7, e35706 (2012).PMC:3387216 PMID:22768030 Kok, M., Koornstra, R.H., Mook, S., Hauptmann, M., Fles, R., Jansen, M.P., Berns, E.M., Linn, S.C. & van ‘t Veer, L.J. Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ERpositive breast cancer. Breast (2012)PMID:22738860 Molloy, T.J., Roepman, P., Naume, B. & van 't Veer, L.J. A prognostic gene expression profile that predicts circulating tumor cell presence in breast cancer patients. PloS one 7, e32426 (2012).PMC:3285692 PMID:22384245 Tian, S., Simon, I., Moreno, V., Roepman, P., Tabernero, J., Snel, M., van ‘t Veer, L.J., Salazar, R., Bernards, R. & Capella, G. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut (2012)PMID:22798500 Verhagen, M.M., Last, J.I., Hogervorst, F.B., Smeets, D.F., Roeleveld, N., Verheijen, F., Catsman-Berrevoets, C.E., Wulffraat, N.M., Cobben, J.M., Hiel, J., Brunt, E.R., Peeters, E.A., Gomez Garcia, E.B., van der Knaap, M.S., Lincke, C.R., Laan, L.A., Tijssen, M.A., van Rijn, M.A., Majoor-Krakauer, D., Visser, M., van 't Veer, L.J., Kleijer, W.J., van de Warrenburg, B.P., Warris, A., de Groot, I.J., de Groot, R., Broeks, A., Preijers, F., Kremer, B.H., Weemaes, C.M., Taylor, M.A., van Deuren, M. & Willemsen, M.A. Presence of ATM protein and residual kinase activity correlates with the phenotype in ataxia-telangiectasia: a genotype-phenotype study. Human mutation 33, 561-71 (2012)PMID:22213089 Wishart, G.C., Bajdik, C.D., Dicks, E., Provenzano, E., Schmidt, M.K., Sherman, M., Greenberg, D.C., Green, A.R., Gelmon, K.A., Kosma, V.M., Olson, J.E., Beckmann, M.W., Winqvist, R., Cross, S.S., Severi, G., Huntsman, D., Pylkas, K., Ellis, I., Page 29 of 38 Laura J. van ‘t Veer – CV 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. Nielsen, T.O., Giles, G., Blomqvist, C., Fasching, P.A., Couch, F.J., Rakha, E., Foulkes, W.D., Blows, F.M., Begin, L.R., van 't Veer, L.J., Southey, M., Nevanlinna, H., Mannermaa, A., Cox, A., Cheang, M., Baglietto, L., Caldas, C., GarciaClosas, M. & Pharoah, P.D. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. British journal of cancer (2012)PMID:22850554 Lips, E.H., Mukhtar, R.A., Yau, C., de Ronde, J.J., Livasy, C., Carey, L.A., Loo, C.E., Vrancken-Peeters, M.J., Sonke, G.S., Berry, D.A., van 't Veer, L.J., Esserman, L.J., Wesseling, J., Rodenhuis, S. & Shelley Hwang, E. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast cancer research and treatment 136, 35-43 (2012)PMID:22961065 Weischer, M., Nordestgaard, B.G., Pharoah, P., Bolla, M.K., Nevanlinna, H., van 't Veer, L.J., Garcia-Closas, M., Hopper, J.L., Hall, P., Andrulis, I.L., Devilee, P., Fasching, P.A., Anton-Culver, H., Lambrechts, D., Hooning, M., Cox, A., Giles, G.G., Burwinkel, B., Lindblom, A., Couch, F.J., Mannermaa, A., Grenaker Alnaes, G., John, E.M., Dork, T., Flyger, H., Dunning, A.M., Wang, Q., Muranen, T.A., van Hien, R., Figueroa, J., Southey, M.C., Czene, K., Knight, J.A., Tollenaar, R.A., Beckmann, M.W., Ziogas, A., Christiaens, M.R., Collee, J.M., Reed, M.W., Severi, G., Marme, F., Margolin, S., Olson, J.E., Kosma, V.M., Kristensen, V.N., Miron, A., Bogdanova, N., Shah, M., Blomqvist, C., Broeks, A., Sherman, M., Phillips, K.A., Li, J., Liu, J., Glendon, G., Seynaeve, C., Ekici, A.B., Leunen, K., Kriege, M., Cross, S.S., Baglietto, L., Sohn, C., Wang, X., Kataja, V., Borresen-Dale, A.L., Meyer, A., Easton, D.F., Schmidt, M.K. & Bojesen, S.E. CHEK2*1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer-Specific Death, and Increased Risk of a Second Breast Cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology (2012)PMID:23109706 Esserman, L.J., Barker, A., Woodcock, J., Buxton, M.B., Berry, D.A., Patterson, R., King Jolly, M., DeMichele, A., Hylton, N., Rubin, E., Parkinson, D., Wholley, D., van 't Veer, L.J., Yee, D., Park, J., Tripathy, D., Perlmutter, J., Buetow, K., Hogarth, M., Gray, J.W. & Dilts, D. A Model for Accelerating Identification and Regulatory Approval of Effective Investigational Agents. Cureus 4, e76 (2012) Stephens, P.J., Tarpey, P.S., Davies, H., Van Loo, P., Greenman, C., Wedge, D.C., Nik-Zainal, S., Martin, S., Varela, I., Bignell, G.R., Yates, L.R., Papaemmanuil, E., Beare, D., Butler, A., Cheverton, A., Gamble, J., Hinton, J., Jia, M., Jayakumar, A., Jones, D., Latimer, C., Lau, K.W., McLaren, S., McBride, D.J., Menzies, A., Mudie, L., Raine, K., Rad, R., Chapman, M.S., Teague, J., Easton, D., Langerod, A., Lee, M.T., Shen, C.Y., Tee, B.T., Huimin, B.W., Broeks, A., Vargas, A.C., Turashvili, G., Martens, J., Fatima, A., Miron, P., Chin, S.F., Thomas, G., Boyault, S., Mariani, O., Lakhani, S.R., van de Vijver, M., van 't Veer, L.J., Foekens, J., Desmedt, C., Sotiriou, C., Tutt, A., Caldas, C., Reis-Filho, J.S., Aparicio, S.A., Salomon, A.V., Borresen-Dale, A.L., Richardson, A.L., Campbell, P.J., Futreal, P.A. & Stratton, M.R. The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400-4 (2012).PMC:3428862 PMID:22722201 Yee, D., Haddad, T., Albain, K., Barker, A., Benz, C., Boughey, J., Buxton, M., Chien, A.J., DeMichele, A., Dilts, D., Elias, A., Haluska, P., Hogarth, M., Hu, A., Hytlon, N., Kaplan, H.G., Kelloff, G.G., Khan, Q., Lang, J., Leyland-Jones, B., Liu, M., Nanda, R., Northfelt, D., Olopade, O.I., Park, J., Parker, B., Parkinson, D., Pearson-White, S., Perlmutter, J., Pusztai, L., Symmans, F., Rugo, H., Tripathy, D., Wallace, A., Wholley, D., van 't Veer, L.J., Berry, D.A. & Esserman, L. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. Journal of clinical oncology 30, 4584-6; author reply 4588-9 (2012)PMID:23169510 Petrillo, L.A., Wolf, D.M., Kapoun, A.M., Wang, N.J., Barczak, A., Xiao, Y., Korkaya, H., Baehner, F., Lewicki, J., Wicha, M., Park, J.W., Spellman, P.T., Gray, J.W., van 't Veer, L.J. & Esserman, L.J. Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors. Breast cancer research and treatment 135, 913-22 (2012)PMID:22941572 Cardoso, F., Costa, A., Norton, L., Cameron, D., Cufer, T., Fallowfield, L., Francis, P., Gligorov, J., Kyriakides, S., Lin, N., Pagani, O., Senkus, E., Thomssen, C., Aapro, M., Bergh, J., Di Leo, A., El Saghir, N., Ganz, P.A., Gelmon, K., Goldhirsch, A., Harbeck, N., Houssami, N., Hudis, C., Kaufman, B., Leadbeater, M., Mayer, M., Rodger, A., Rugo, H., Sacchini, V., Sledge, G., van 't Veer, L.J., Viale, G., Krop, I. & Winer, E. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 21, 242-52 (2012)PMID:22425534 Drukker, C.A., Bueno-de-Mesquita, J.M., Retel, V.P., van Harten, W.H., van Tinteren, H., Wesseling, J., Roumen, R.M., Knauer, M., van 't Veer, L.J., Sonke, G.S., Rutgers, E.J., van de Vijver, M.J. & Linn, S.C. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. International journal of cancer 133, 929-36 (2013)PMID:23371464 Bruin, S.C., de Ronde, J.J., Wiering, B., Braaf, L.M., de Wilt, J.H., Vincent, A.D., van Velthuysen, M.L., Ruers, T.J., Wessels, L.F. & van 't Veer, L.J. Selection of Patients for Hepatic Surgery of Colorectal Cancer Liver Metastasis Based on Genomic Aberrations. Annals of surgical oncology (2013)PMID:23783809 Elson, S.L., Hiatt, R.A., Anton-Culver, H., Howell, L.P., Naeim, A., Parker, B.A., van 't Veer, L.J., Hogarth, M., Pierce, J.P., Duwors, R.J., Hajopoulos, K. & Esserman, L.J. The Athena Breast Health Network: developing a rapid learning system in breast cancer prevention, screening, treatment, and care. Breast cancer research and treatment 140, 417-25 (2013)PMID:23887672 Page 30 of 38 Laura J. van ‘t Veer – CV 204. Esserman, L., Ozanne, E. & van 't Veer, L.J. Will early detection for breast cancer ever work? Clinical chemistry 59, 190-3 (2013)PMID:23193061 205. Garcia-Closas, M., Couch, F.J., Lindstrom, S., Michailidou, K., Schmidt, M.K., Brook, M.N., Orr, N., Rhie, S.K., Riboli, E., Feigelson, H.S., Le Marchand, L., Buring, J.E., Eccles, D., Miron, P., Fasching, P.A., Brauch, H., Chang-Claude, J., Carpenter, J., Godwin, A.K., Nevanlinna, H., Giles, G.G., Cox, A., Hopper, J.L., Bolla, M.K., Wang, Q., Dennis, J., Dicks, E., Howat, W.J., Schoof, N., Bojesen, S.E., Lambrechts, D., Broeks, A., Andrulis, I.L., Guenel, P., Burwinkel, B., Sawyer, E.J., Hollestelle, A., Fletcher, O., Winqvist, R., Brenner, H., Mannermaa, A., Hamann, U., Meindl, A., Lindblom, A., Zheng, W., Devillee, P., Goldberg, M.S., Lubinski, J., Kristensen, V., Swerdlow, A., Anton-Culver, H., Dork, T., Muir, K., Matsuo, K., Wu, A.H., Radice, P., Teo, S.H., Shu, X.O., Blot, W., Kang, D., Hartman, M., Sangrajrang, S., Shen, C.Y., Southey, M.C., Park, D.J., Hammet, F., Stone, J., van 't Veer, L.J., Rutgers, E.J., Lophatananon, A., Stewart-Brown, S., Siriwanarangsan, P., Peto, J., Schrauder, M.G., Ekici, A.B., Beckmann, M.W., Dos Santos Silva, I., Johnson, N., Warren, H., Tomlinson, I., Kerin, M.J., Miller, N., Marme, F., Schneeweiss, A., Sohn, C., Truong, T., Laurent-Puig, P., Kerbrat, P., Nordestgaard, B.G., Nielsen, S.F., Flyger, H., Milne, R.L., Perez, J.I., Menendez, P., Muller, H., Arndt, V., Stegmaier, C., Lichtner, P., Lochmann, M., Justenhoven, C., Ko, Y.D., Muranen, T.A., Aittomaki, K., Blomqvist, C., Greco, D., Heikkinen, T., Ito, H., Iwata, H., Yatabe, Y., Antonenkova, N.N., Margolin, S., Kataja, V., Kosma, V.M., Hartikainen, J.M., Balleine, R., Tseng, C.C., Berg, D.V., Stram, D.O., Neven, P., Dieudonne, A.S., Leunen, K., Rudolph, A., Nickels, S., Flesch-Janys, D., Peterlongo, P., Peissel, B., Bernard, L., Olson, J.E., Wang, X., Stevens, K., Severi, G., Baglietto, L., McLean, C., Coetzee, G.A., Feng, Y., Henderson, B.E., Schumacher, F., Bogdanova, N.V., Labreche, F., Dumont, M., Yip, C.H., Taib, N.A., Cheng, C.Y., Shrubsole, M., Long, J., Pylkas, K., Jukkola-Vuorinen, A., Kauppila, S., Knight, J.A., Glendon, G., Mulligan, A.M., Tollenaar, R.A., Seynaeve, C.M., Kriege, M., Hooning, M.J., van den Ouweland, A.M., van Deurzen, C.H., Lu, W., Gao, Y.T., Cai, H., Balasubramanian, S.P., Cross, S.S., Reed, M.W., Signorello, L., Cai, Q., Shah, M., Miao, H., Chan, C.W., Chia, K.S., Jakubowska, A., Jaworska, K., Durda, K., Hsiung, C.N., Wu, P.E., Yu, J.C., Ashworth, A., Jones, M., Tessier, D.C., Gonzalez-Neira, A., Pita, G., Alonso, M.R., Vincent, D., Bacot, F., Ambrosone, C.B., Bandera, E.V., John, E.M., Chen, G.K., Hu, J.J., Rodriguez-Gil, J.L., Bernstein, L., Press, M.F., Ziegler, R.G., Millikan, R.M., Deming-Halverson, S.L., Nyante, S., Ingles, S.A., Waisfisz, Q., Tsimiklis, H., Makalic, E., Schmidt, D., Bui, M., Gibson, L., Muller-Myhsok, B., Schmutzler, R.K., Hein, R., Dahmen, N., Beckmann, L., Aaltonen, K., Czene, K., Irwanto, A., Liu, J., Turnbull, C., Rahman, N., Meijers-Heijboer, H., Uitterlinden, A.G., Rivadeneira, F., Olswold, C., Slager, S., Pilarski, R., Ademuyiwa, F., Konstantopoulou, I., Martin, N.G., Montgomery, G.W., Slamon, D.J., Rauh, C., Lux, M.P., Jud, S.M., Bruning, T., Weaver, J., Sharma, P., Pathak, H., Tapper, W., Gerty, S., Durcan, L., Trichopoulos, D., Tumino, R., Peeters, P.H., Kaaks, R., Campa, D., Canzian, F., Weiderpass, E., Johansson, M., Khaw, K.T., Travis, R., Clavel-Chapelon, F., Kolonel, L.N., Chen, C., Beck, A., Hankinson, S.E., Berg, C.D., Hoover, R.N., Lissowska, J., Figueroa, J.D., Chasman, D.I., Gaudet, M.M., Diver, W.R., Willett, W.C., Hunter, D.J., Simard, J., Benitez, J., Dunning, A.M., Sherman, M.E., Chenevix-Trench, G., Chanock, S.J., Hall, P., Pharoah, P.D., Vachon, C., Easton, D.F., Haiman, C.A. & Kraft, P. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nature genetics 45, 392-8, 398e1-2 (2013)PMID:23535733 206. Michailidou, K., Hall, P., Gonzalez-Neira, A., Ghoussaini, M., Dennis, J., Milne, R.L., Schmidt, M.K., Chang-Claude, J., Bojesen, S.E., Bolla, M.K., Wang, Q., Dicks, E., Lee, A., Turnbull, C., Rahman, N., Fletcher, O., Peto, J., Gibson, L., Dos Santos Silva, I., Nevanlinna, H., Muranen, T.A., Aittomaki, K., Blomqvist, C., Czene, K., Irwanto, A., Liu, J., Waisfisz, Q., Meijers-Heijboer, H., Adank, M., van der Luijt, R.B., Hein, R., Dahmen, N., Beckman, L., Meindl, A., Schmutzler, R.K., Muller-Myhsok, B., Lichtner, P., Hopper, J.L., Southey, M.C., Makalic, E., Schmidt, D.F., Uitterlinden, A.G., Hofman, A., Hunter, D.J., Chanock, S.J., Vincent, D., Bacot, F., Tessier, D.C., Canisius, S., Wessels, L.F., Haiman, C.A., Shah, M., Luben, R., Brown, J., Luccarini, C., Schoof, N., Humphreys, K., Li, J., Nordestgaard, B.G., Nielsen, S.F., Flyger, H., Couch, F.J., Wang, X., Vachon, C., Stevens, K.N., Lambrechts, D., Moisse, M., Paridaens, R., Christiaens, M.R., Rudolph, A., Nickels, S., Flesch-Janys, D., Johnson, N., Aitken, Z., Aaltonen, K., Heikkinen, T., Broeks, A., van ‘t Veer, L.J., van der Schoot, C.E., Guenel, P., Truong, T., Laurent-Puig, P., Menegaux, F., Marme, F., Schneeweiss, A., Sohn, C., Burwinkel, B., Zamora, M.P., Perez, J.I., Pita, G., Alonso, M.R., Cox, A., Brock, I.W., Cross, S.S., Reed, M.W., Sawyer, E.J., Tomlinson, I., Kerin, M.J., Miller, N., Henderson, B.E., Schumacher, F., Le Marchand, L., Andrulis, I.L., Knight, J.A., Glendon, G., Mulligan, A.M., Lindblom, A., Margolin, S., Hooning, M.J., Hollestelle, A., van den Ouweland, A.M., Jager, A., Bui, Q.M., Stone, J., Dite, G.S., Apicella, C., Tsimiklis, H., Giles, G.G., Severi, G., Baglietto, L., Fasching, P.A., Haeberle, L., Ekici, A.B., Beckmann, M.W., Brenner, H., Muller, H., Arndt, V., Stegmaier, C., Swerdlow, A., Ashworth, A., Orr, N., Jones, M., Figueroa, J., Lissowska, J., Brinton, L., Goldberg, M.S., Labreche, F., Dumont, M., Winqvist, R., Pylkas, K., JukkolaVuorinen, A., Grip, M., Brauch, H., Hamann, U., Bruning, T., Radice, P., Peterlongo, P., Manoukian, S., Bonanni, B., Devilee, P., Tollenaar, R.A., Seynaeve, C., van Asperen, C.J., Jakubowska, A., Lubinski, J., Jaworska, K., Durda, K., Mannermaa, A., Kataja, V., Kosma, V.M., Hartikainen, J.M., Bogdanova, N.V., Antonenkova, N.N., Dork, T., Kristensen, V.N., Anton-Culver, H., Slager, S., Toland, A.E., Edge, S., Fostira, F., Kang, D., Yoo, K.Y., Noh, D.Y., Matsuo, K., Ito, H., Iwata, H., Sueta, A., Wu, A.H., Tseng, C.C., Van Den Berg, D., Stram, D.O., Shu, X.O., Lu, W., Gao, Y.T., Cai, H., Teo, S.H., Yip, C.H., Phuah, S.Y., Cornes, B.K., Hartman, M., Miao, H., Lim, W.Y., Sng, J.H., Muir, K., Lophatananon, A., Stewart-Brown, S., Siriwanarangsan, P., Shen, C.Y., Hsiung, C.N., Wu, P.E., Ding, S.L., Sangrajrang, S., Gaborieau, V., Brennan, P., McKay, J., Blot, W.J., Signorello, L.B., Cai, Q., Zheng, W., Deming-Halverson, S., Shrubsole, M., Long, J., Page 31 of 38 Laura J. van ‘t Veer – CV 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. Simard, J., Garcia-Closas, M., Pharoah, P.D., Chenevix-Trench, G., Dunning, A.M., Benitez, J. & Easton, D.F. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature genetics 45, 353-61, 361e1-2 (2013)PMID:23535729 Mittempergher, L., Saghatchian, M., Wolf, D.M., Michiels, S., Canisius, S., Dessen, P., Delaloge, S., Lazar, V., Benz, S.C., Tursz, T., Bernards, R. & van 't Veer, L.J. A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences. Molecular oncology (2013)PMID:23910573 Saghatchian, M., Mook, S., Pruneri, G., Viale, G., Glas, A.M., Guerin, S., Cardoso, F., Piccart, M., Tursz, T., Delaloge, S. & van 't Veer, L. J. Additional prognostic value of the 70-gene signature (MammaPrint((R))) among breast cancer patients with 4-9 positive lymph nodes. Breast (2013)PMID:23347730 Timmerman, L.A., Holton, T., Yuneva, M., Louie, R.J., Padro, M., Daemen, A., Hu, M., Chan, D.A., Ethier, S.P., van 't Veer, L.J., Polyak, K., McCormick, F. & Gray, J.W. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 24, 450-65 (2013).PMC:3931310 PMID:24094812 Abernethy, A., Abrahams, E., Barker, A., Buetow, K., Burkholder, R., Dalton, W.S., Foti, M., Frueh, F., Gaynor, R.B., Kean, M., Khan, Z., Lessor, T., Lichtenfeld, J.L., Mendelsohn, J. & van't Veer, L. Turning the tide against cancer through sustained medical innovation: the pathway to progress. Clin Cancer Res 20, 1081-6 (2014)PMID:24523437 Agarwal, D., Pineda, S., Michailidou, K., Herranz, J., Pita, G., Moreno, L.T., Alonso, M.R., Dennis, J., Wang, Q., Bolla, M.K., Meyer, K.B., Menendez-Rodriguez, P., Hardisson, D., Mendiola, M., Gonzalez-Neira, A., Lindblom, A., Margolin, S., Swerdlow, A., Ashworth, A., Orr, N., Jones, M., Matsuo, K., Ito, H., Iwata, H., Kondo, N., Hartman, M., Hui, M., Lim, W.Y., Iau, P.T., Sawyer, E., Tomlinson, I., Kerin, M., Miller, N., Kang, D., Choi, J., Park, S.K., Noh, D., Hopper, J.L., Schmidt, D.F., Makalic, E., Southey, M.C., Teo, S.H., Yip, C.H., Sivanandan, K., Tay, W., Brauch, H., Bruning, T., Hamann, U., Dunning, A.M., Shah, M., Andrulis, I.L., Knight, J.A., Glendon, G., Tchatchou, S., Schmidt, M.K., Broeks, A., Rosenberg, E.H., van't Veer, L.J., Fasching, P.A., Renner, S.P., Ekici, A.B., Beckmann, M.W., Shen, C., Hsiung, C., Yu, J., Hou, M., Blot, W., Cai, Q., Wu, A.H., Tseng, C., Van Den Berg, D., Stram, D.O., Cox, A., Brock, I.W., Reed, M.W., Muir, K., Lophatananon, A., Stewart-Brown, S., Siriwanarangsan, P., Zheng, W., Deming-Halverson, S., Shrubsole, M.J., Long, J., Shu, X., Lu, W., Gao, Y., Zhang, B., Radice, P., Peterlongo, P., Manoukian, S., Mariette, F., Sangrajrang, S., McKay, J., Couch, F.J., Toland, A.E., Yannoukakos, D., Fletcher, O., Johnson, N., dos Santos Silva, I., Peto, J., Marme, F., Burwinkel, B., Guenel, P., Truong, T., Sanchez, M., Mulot, C., Bojesen, S.E., Nordestgaard, B.G., Flyer, H., Brenner, H., Dieffenbach, A.K., Arndt, V., Stegmaier, C., Mannermaa, A., Kataja, V., Kosma, V., Hartikainen, J.M., Lambrechts, D., Yesilyurt, B.T., Floris, G., Leunen, K., Chang-Claude, J., Rudolph, A., Seibold, P., Flesch-Janys, D., Wang, X., Olson, J.E., Vachon, C., Purrington, K., Giles, G.G., Severi, G., Baglietto, L., Haiman, C.A., Henderson, B.E., Schumacher, F., Marchand, L.L., Simard, J., Dumont, M., Goldberg, M.S., Labreche, F., Winqvist, R., Pylkas, K., Jukkola-Vuorinen, A., Grip, M., Devilee, P., Tollenaar, R.A., Seynaeve, C., Garcia-Closas, M., Chanock, S.J., Lissowska, J., Figueroa, J.D., Czene, K., Eriksson, M., Humphreys, K., Darabi, H., Hooning, M.J., Kriege, M., Collee, J.M., Tilanus-Linthorst, M., Li, J., Jakubowska, A., Lubinski, J., Jaworska-Bieniek, K., Durda, K., Nevanlinna, H., Muranen, T.A., Aittomaki, K., Blomqvist, C., Bogdanova, N., Dork, T., Hall, P., Chenevix-Trench, G., Easton, D.F., Pharroah, P.D., Arias-Perez, J.I., Zamora, P., Benitez, J. & Milne, R.L. FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. British journal of cancer 110, 1088-100 (2014).PMC:3929867 PMID:24548884 Brohet, R.M., Velthuizen, M.E., Hogervorst, F.B., Meijers-Heijboer, H.E., Seynaeve, C., Collee, M.J., Verhoef, S., Ausems, M.G., Hoogerbrugge, N., van Asperen, C.J., Gomez Garcia, E., Menko, F., Oosterwijk, J.C., Devilee, P., van't Veer, L.J., van Leeuwen, F.E., Easton, D.F., Rookus, M.A. & Antoniou, A.C. Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. J Med Genet 51, 98107 (2014)PMID:24285858 Drukker, C.A., Nijenhuis, M.V., Bueno-de-Mesquita, J.M., Retel, V.P., van Harten, W.H., van Tinteren, H., Wesseling, J., Schmidt, M.K., Van't Veer, L.J., Sonke, G.S., Rutgers, E.J., van de Vijver, M.J. & Linn, S.C. Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms. Breast cancer research and treatment 145, 697-705 (2014).PMC:4031388 PMID:24760482 Drukker, C.A., Schmidt, M.K., Rutgers, E.J., Cardoso, F., Kerlikowske, K., Esserman, L.J., van Leeuwen, F.E., Pijnappel, R.M., Slaets, L., Bogaerts, J. & Van't Veer, L.J. Mammographic screening detects low-risk tumor biology breast cancers. Breast cancer research and treatment 144, 103-11 (2014).PMC:3924026 PMID:24469641 Drukker, C.A., van Tinteren, H., Schmidt, M.K., Rutgers, E.J., Bernards, R., van de Vijver, M.J. & Van't Veer, L.J. Longterm impact of the 70-gene signature on breast cancer outcome. Breast cancer research and treatment 143, 587-92 (2014).PMC:3907672 PMID:24445566 Elias, S.G., Adams, A., Wisner, D.J., Esserman, L.J., van 't Veer, L.J., Mali, W.P., Gilhuijs, K.G. & Hylton, N.M. Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev (2014)PMID:24807204 Sapino, A., Roepman, P., Linn, S.C., Snel, M.H., Delahaye, L.J., van den Akker, J., Glas, A.M., Simon, I.M., Barth, N., de Snoo, F.A., van 't Veer, L.J., Molinaro, L., Berns, E.M., Wesseling, J., Riley, L.B., Anderson, D., Nguyen, B. & Cox, C.E. Page 32 of 38 Laura J. van ‘t Veer – CV 218. 219. 220. 221. 222. MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue. J Mol Diagn 16, 190-7 (2014)PMID:24378251 Viale, G., Slaets, L., Bogaerts, J., Rutgers, E., van't Veer, L., Piccart-Gebhart, M.J., de Snoo, F.A., Stork-Sloots, L., Russo, L., Dell'Orto, P., van den Akker, J., Glas, A. & Cardoso, F. High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. Ann Oncol 25, 816-23 (2014).PMC:3969556 PMID:24667714 Wolf, D.M., Lenburg, M.E., Yau, C., Boudreau, A. & van 't Veer, L.J. Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity. PloS one 9, e88309 (2014).PMC:3917875 PMID:24516633 Purrington, K.S., Slettedahl, S., Bolla, M.K., Michailidou, K., Czene, K., Nevanlinna, H., Bojesen, S.E., Andrulis, I.L., Cox, A., Hall, P., Carpenter, J., Yannoukakos, D., Haiman, C.A., Fasching, P.A., Mannermaa, A., Winqvist, R., Brenner, H., Lindblom, A., Chenevix-Trench, G., Benitez, J., Swerdlow, A., Kristensen, V., Guenel, P., Meindl, A., Darabi, H., Eriksson, M., Fagerholm, R., Aittomaki, K., Blomqvist, C., Nordestgaard, B.G., Nielsen, S.F., Flyger, H., Wang, X., Olswold, C., Olson, J.E., Mulligan, A.M., Knight, J.A., Tchatchou, S., Reed, M.W., Cross, S.S., Liu, J., Li, J., Humphreys, K., Clarke, C., Scott, R., Fostira, F., Fountzilas, G., Konstantopoulou, I., Henderson, B.E., Schumacher, F., Le Marchand, L., Ekici, A.B., Hartmann, A., Beckmann, M.W., Hartikainen, J.M., Kosma, V.M., Kataja, V., Jukkola-Vuorinen, A., Pylkas, K., Kauppila, S., Dieffenbach, A.K., Stegmaier, C., Arndt, V., Margolin, S., Balleine, R., Arias Perez, J.I., Pilar Zamora, M., Menendez, P., Ashworth, A., Jones, M., Orr, N., Arveux, P., Kerbrat, P., Truong, T., Bugert, P., Toland, A.E., Ambrosone, C.B., Labreche, F., Goldberg, M.S., Dumont, M., Ziogas, A., Lee, E., Dite, G.S., Apicella, C., Southey, M.C., Long, J., Shrubsole, M., Deming-Halverson, S., Ficarazzi, F., Barile, M., Peterlongo, P., Durda, K., Jaworska-Bieniek, K., Tollenaar, R.A., Seynaeve, C., Bruning, T., Ko, Y.D., Van Deurzen, C.H., Martens, J.W., Kriege, M., Figueroa, J.D., Chanock, S.J., Lissowska, J., Tomlinson, I., Kerin, M.J., Miller, N., Schneeweiss, A., Tapper, W.J., Gerty, S.M., Durcan, L., McLean, C., Milne, R.L., Baglietto, L., Dos Santos Silva, I., Fletcher, O., Johnson, N., Van, T.V.L.J., Cornelissen, S., Forsti, A., Torres, D., Rudiger, T., Rudolph, A., Flesch-Janys, D., Nickels, S., Weltens, C., Floris, G., Moisse, M., Dennis, J., Wang, Q., Dunning, A.M., Shah, M., Brown, J., Simard, J., Anton-Culver, H., Neuhausen, S.L., Hopper, J.L., Bogdanova, N., Dork, T., Zheng, W., Radice, P., Jakubowska, A., Lubinski, J., Devillee, P., Brauch, H., Hooning, M., Garcia-Closas, M., Sawyer, E., Burwinkel, B., Marmee, F., Eccles, D.M., Giles, G.G., Peto, J., Schmidt, M., Broeks, A., Hamann, U., Chang-Claude, J., Lambrechts, D., Pharoah, P.D., Easton, D., Pankratz, V.S., Slager, S., Vachon, C.M. & Couch, F.J. Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. Hum Mol Genet (2014)PMID:24927736 Li, J., Lindstrom, L.S., Foo, J.N., Rafiq, S., Schmidt, M.K., Pharoah, P.D., Michailidou, K., Dennis, J., Bolla, M.K., Wang, Q., Van 't Veer, L.J., Cornelissen, S., Rutgers, E., Southey, M.C., Apicella, C., Dite, G.S., Hopper, J.L., Fasching, P.A., Haeberle, L., Ekici, A.B., Beckmann, M.W., Blomqvist, C., Muranen, T.A., Aittomaki, K., Lindblom, A., Margolin, S., Mannermaa, A., Kosma, V.M., Hartikainen, J.M., Kataja, V., Chenevix-Trench, G., Investigators, k., Phillips, K.A., McLachlan, S.A., Lambrechts, D., Thienpont, B., Smeets, A., Wildiers, H., Chang-Claude, J., Flesch-Janys, D., Seibold, P., Rudolph, A., Giles, G.G., Baglietto, L., Severi, G., Haiman, C.A., Henderson, B.E., Schumacher, F., Le Marchand, L., Kristensen, V., Alnaes, G.I., Borresen-Dale, A.L., Nord, S., Winqvist, R., Pylkas, K., Jukkola-Vuorinen, A., Grip, M., Andrulis, I.L., Knight, J.A., Glendon, G., Tchatchou, S., Devilee, P., Tollenaar, R., Seynaeve, C., Hooning, M., Kriege, M., Hollestelle, A., van den Ouweland, A., Li, Y., Hamann, U., Torres, D., Ulmer, H.U., Rudiger, T., Shen, C.Y., Hsiung, C.N., Wu, P.E., Chen, S.T., Teo, S.H., Taib, N.A., Har Yip, C., Fuang Ho, G., Matsuo, K., Ito, H., Iwata, H., Tajima, K., Kang, D., Choi, J.Y., Park, S.K., Yoo, K.Y., Maishman, T., Tapper, W.J., Dunning, A., Shah, M., Luben, R., Brown, J., Khor, C.C., Eccles, D.M., Nevanlinna, H., Easton, D., Humphreys, K., Liu, J., Hall, P. & Czene, K. 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. Nat Commun 5, 4051 (2014)PMID:24937182 Johnson, N., Dudbridge, F., Orr, N., Gibson, L., Jones, M.E., Schoemaker, M.J., Folkerd, E.J., Haynes, B.P., Hopper, J.L., Southey, M.C., Dite, G.S., Apicella, C., Schmidt, M.K., Broeks, A., Van, T.V.L.J., Atsma, F., Muir, K., Lophatananon, A., Fasching, P.A., Beckmann, M.W., Ekici, A.B., Renner, S.P., Sawyer, E., Tomlinson, I., Kerin, M., Miller, N., Burwinkel, B., Marme, F., Schneeweiss, A., Sohn, C., Guenel, P., Truong, T., Cordina, E., Menegaux, F., Bojesen, S.E., Nordestgaard, B.G., Flyger, H., Milne, R., Zamora, M.P., Arias Perez, J.I., Benitez, J., Bernstein, L., Anton-Culver, H., Ziogas, A., Clarke Dur, C., Brenner, H., Muller, H., Arndt, V., Dieffenbach, A.K., Meindl, A., Heil, J., Bartram, C.R., Schmutzler, R.K., Brauch, H., Justenhoven, C., Ko, Y.D., Nevanlinna, H., Muranen, T.A., Aittomaki, K., Blomqvist, C., Matsuo, K., Dork, T., Bogdanova, N.V., Antonenkova, N.N., Lindblom, A., Mannermaa, A., Kataja, V., Kosma, V.M., Hartikainen, J.M., Chenevix-Trench, G., Beesley, J., Wu, A.H., Van den Berg, D., Tseng, C.C., Lambrechts, D., Smeets, D., Neven, P., Wildiers, H., Chang-Claude, J., Rudolph, A., Nickels, S., Flesch-Janys, D., Radice, P., Peterlongo, P., Bonanni, B., Pensotti, V., Couch, F.J., Olson, J.E., Wang, X., Fredericksen, Z., Pankratz, V.S., Giles, G.G., Severi, G., Baglietto, L., Haiman, C., Simard, J., Goldberg, M.S., Labreche, F., Dumont, M., Soucy, P., Teo, S., Yip, C.H., Phuah, S.Y., Cornes, B.K., Kristensen, V.N., Grenaker Alnaes, G., Borresen-Dale, A.L., Zheng, W., Winqvist, R., Pylkas, K., Jukkola-Vuorinen, A., Grip, M., Andrulis, I.L., Knight, J.A., Glendon, G., Mulligan, A.M., Devillee, P., Figueroa, J., Chanock, S.J., Lissowska, J., Sherman, M.E., Hall, P., Schoof, N., Hooning, M., Hollestelle, A., Oldenburg, R.A., Tilanus-Linthorst, M., Liu, J., Cox, A., Brock, I.W., Reed, M.W., Cross, S.S., Blot, W., Signorello, L.B., Pharoah, P.D., Dunning, A.M., Shah, M., Kang, D., Noh, D.Y., Park, S.K., Choi, J.Y., Hartman, Page 33 of 38 Laura J. van ‘t Veer – CV M., Miao, H., Lim, W.Y., Tang, A., Hamann, U., Forsti, A., Rudiger, T., Ulmer, H.U., Jakubowska, A., Lubinski, J., Jaworska-Bieniek, K., Durda, K., Sangrajrang, S., Gaborieau, V., Brennan, P., McKay, J., Slager, S., Toland, A.E., Vachon, C., Yannoukakos, D., Shen, C.Y., Yu, J.C., Huang, C.S., Hou, M.F., Gonzalez-Neira, A., Tessier, D.C., Vincent, D., Bacot, F., Luccarini, C., Dennis, J., Michailidou, K., Bolla, M.K., Wang, J., Easton, D.F., Garcia-Closas, M., Dowsett, M., Ashworth, A., Swerdlow, A.J., Peto, J., Dos Santos Silva, I. & Fletcher, O. Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer Res 16, R51 (2014)PMID:24887515 NON-PEER REVIEWED PUBLICATIONS AND OTHER CREATIVE ACTIVITIES: Review Articles 1. Van ‘t Veer LJ, Weigelt B. Road map to metastasis. Nat Medicine 2003; 9: 999-1000. 2. Weigelt B, Van ‘t Veer LJ. Hard-wired genotype in metastatic breast cancer. Cell Cycle 2004; 3: 756-7. 3. De Jong D, Van ‘t Veer LJ. Tools for molecular risk-stratification for clinical purposes: CLL as a prototype. Eur J Hum Genet. 2004; 12: 423. 4. Van ’t Veer LJ, Paik S, Hayes DF. Gene expression profiling of breast cancer: A New Tumor Marker. J Clin Oncol. 2005; 23: 1631-5. 5. Weigelt B, Peterse JL, Van ‘t Veer LJ. Breast cancer metastasis – markers and models. Nat Rev Cancer 2005; 5: 591-602. 6. Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison J, Bines J, Mook S, Decker N, Therasse P, Rutgers E, Van ‘t Veer LJ, Piccart M, on behalf of the TRANSBIG consortium. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol. 2006; 10: 540-51. 7. Mook S, Van ‘t Veer LJ, Rutgers EJTh, Piccart-Gebhart MJ, Cardoso F. Individualization of therapy using Mammaprint®: from development to the MINDACT trial. Cancer Gen & Proteom. 2007; 4: 147-56. 8. Molloy, T.J., Van ‘t Veer, L.J. (2008) Recent advances in metastasis research. Curr Opin Genet & Dev 18, 35-41. 9. Cardoso, F., Piccart-Gebhart, M., Van ‘t Veer, L.J., Rutgers, E., the TRANSBIG Consortium (2007) The MINDACT trial: the first prospective validation of a genomic tool. Mol Oncol 1, 246-251. 10. Cardoso, F., Van ’t Veer, L.J., Rutgers, E., Loi, S., Mook, S., Piccart-Gebhart, M.J. (2008) Clinical Application of the 70gene profile: the MINDACT trial. J Clin Oncol 26, 729-735. 11. Van ‘t Veer, L.J., Bernards R (2008) Insight Review: Enabling personalized cancer medicine through analysis of geneexpression patterns. Nature 452, 564-570. 12. Broeks A, Schmidt, MK., Sherman, ME., Couch, FJ., Hopper, J. (ABCFS), Van ’t Veer, LJ., de Groot, R., Smit, V. (ABCS), Fashing, P. (BBCC), Burwinkel, B. (BSUCH), Bojesen, S. (CGPS), Milne, R. (CNIO-BCS), Brauch, H. (GENICA), ChangClaude, J. (GESBC), Doerk, T. (HABCS), Nevanlinna, H. (HEBCS), Lindblom, A. (KARBAC), Mannermaa, A. (KBCP), Chenevix-Trench, G. (KConFab), Lambrechts, D. (LMBC), (MARIE), Kosel, M., Fredericksen, ZS., Wang, X. (MCBCS), Giles, G., Southey, M. (MCCS), Haiman, C. (MEC), Alnæs, GG., Kristensen, V. (NBCS), Hunter, D. (NHS), Andrulis, I., Ozcelik, H. (OFBCR), Devilee, P., Huijts, P. (ORIGO), Chanock, S., Lissowska, J., Yang, R. (PBCS), Hooning, M., Hollestelle, A. (RBCS), Hall, P., Liu, J. (SASBAC), Cox, A. (SBCS), Dunning, A., Easton, D., Humphreys, M., Caldas, C. (SEARCH), Lubinski, J. (SZBCS), Gaborieau, V. (TBCS), Shen, CY. (TWBCS), Anton-Culver, H., Ziogas, A. (UCIBCS), Pharoah, P., Garcia-Closas, M. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: Findings from the Breast Cancer Association Consortium. Unpublished 2011. Chapters in Books and Local Papers 1. Schrier, P.I., Van ‘t Veer, L.J., Bergman, W. (1994) Human Melanoma Genetics: Involvement of oncogenes and tumor suppressor genes. In: Malignant Melanoma: Medical and surgical management. Eds: Lejeune, F.J. et al.. McGraw-Hill, New York, USA; p65-80. 2. De Jong, D., Richel, D., Schenkeveld, C., Boerrigter, L., Van ‘t Veer, L.J. (1997) Oligoclonal peripheral T-cell lymphocytosis as a result of aberrant T-cell development in a cortical thymoma. In: Epithelial tumors of the thymus. Eds.: Marx, A., MüllerHermelink, H.K.. Plenum Press, New York USA, p179-185. Page 34 of 38 Laura J. van ‘t Veer – CV 3. Van Zandwijk, N., Van ‘t Veer, L.J. (1998) Antioxidants and the chemoprevention of lung cancer. In: Lung tumors: fundamental biology and clinical management Eds.: Brambilla, C., Brambilla, E.. Marcel Dekker Inc, New York USA, p321-334. 4. Menko, F.J., Van ‘t Veer, L.J. (1998) Kanker. In: Klinische Genetica. Eds.: Leschot, N.J., Brunner, H.G.. Elsevier/Bunge, Utrecht, chapt. 1-10: p8-13, chapt. 17: p145-153. 5. Van ‘t Veer, L.J., Hofstra, R., Tops, C., Ligtenberg, M. (1998) Microsatelliet instabiliteit als ondersteuning van de klinische diagnose HNPCC. LOD Nieuwsbrief nr.6, p12-13. 6. Kersten, M.J., Surachno, S., Koopman, M.G., ten Berge, R.J.M., Van ‘t Veer, L.J., Van Oers, M.H.J. (1999) Het Epstein-Barr virus, een gevaarlijke verstekeling. Ned Tijdschr v Gen 143, 360-364. 7. Taal, B.G., Van Loon, H., Kahn, N., De Jong, D., Vasen, H.F.A., Van ‘t Veer, L.J. (1999) De rol van genetische factoren bij het ontstaan van maagcarcinoom. Ned Tijdschr v Gen 143, 342-346. 8. Fischer J.R., Baas P., Becker H.D., Chyczewski L., Dienemann H., Drings P., Ebert W., Herth F., Hoffmann H., Laudanski J., Lahm H., Manegold C., Monzo M., Mooi W.J., Muley T., Neuner A., Niklinski J., Niklinska W., Rosell R., Taron M., Van 't Veer L.J., Werle B., van Zandwijk N. (2002) Report from the first Meeting of the 'European Network on Translational Research in Lung Cancer Amsterdam-Barcelona- Bialystok-Heidelberg', Heidelberg, Germany, July 25, 2001. Lung Cancer 36, 221-224. 9. Broeks, A., Van ‘t Veer, L.J., Ottenheim, C., Hiel, J., Kleijer, W.J., Weemaes, C. (2003) Van gen naar ziekte: Ataxia Teleangiectasia. Ned Tijdschr v Gen 147, 386-389. 10. Ellis I.O., Schnitt S.J., Sastre-Garau X., Bussolati G., Tavassoli F.A., Eusebi V., Peterse J.L., Mukai K., Tabar L., Jacquemier J., Cornelisse C.J., Sasco A.J., Kaaks R., Pisani P., Goldgar D.E., Devilee P., Cleton-Jansen M.J., Borresen-Dale A.L., Van 't Veer L.J., Sapino A. (2003) Invasive breast carcinoma, chapt 2 In:. WHO Pathology and genetics of Tumours of the Breast and Female Genital Organs. Eds: Tavassoli FA, Devilee P. WHO Blue Books, Lyon: IARC Press, 13-59. 11. Broeks, A., Van ‘t Veer. L.J., Borreson, A.L., Hall, J (2003) Ataxia Telangiectasia Syndrome, chapt. 8.6. In: WHO Pathology and genetics of Tumours of the Breast and Female Genital Organs. Eds: Tavassoli, FA, Devilee, P. WHO Blue Books, Lyon: IARC Press, 361-363. 12. Schmidt, M.K., Van Leeuwen, F.E., Klaren, H.M., Tollenaar, R.A.E.M., Van ‘t Veer, L.J. (2004) Genetisch onderzoek met opgeslagen lichaamsmateriaal: een coderingsprocedure met optimaal gebruik van informatie bij behoud van privacy. Ned Tijdschr v Gen 148, 564-568. 13. Van ‘t Veer, L.J., Rodenhuis, S., Van de Vijver, M.J. (2005) Prognostische betekenis van het genexpressie-profiel van mammatumoren, bepaald met DNA-micro-arrays. Ned Tijdschr v Gen 149, 638-646. 14. Lippman M.E., Benz C., Chinnaiyan A., Flockhart D., Harris A., Hudis C., Osborne C.K., Press M.F., Rae J., Sledge G.W., Van ’t Veer L.J., Wicha M. (2004) Consensus statement: Expedition Inspiration Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'. Breast Cancer Res Treat 90:1-3. 15. Van de Vijver, M.J., Bueno de Mesquita, J.M., Berns, E.M., Van ’t Veer, L.J., Foekens, J.A. (2006) Genexpressie profielen als prognostische en predictieve tests. In: Handboek Borstkanker. Eds: T Wobbes, H. Nortier, C.C. Koning: Tijdstroom. 16. Mook, S., Cardoso, F., Van ’t Veer, L.J. (2008) Personalized medicine by the use of microarray gene expression profiling. In: Pharmacogenetics of breast cancer – towards the individualization of therapy. Eds: B. Leland-Jones: Informa Healthcare. 17. Schmoll, H.J., Van ’t Veer, L.J., Vermorken, J., Schrijvers, D.: Editors. (2009) European Society for Medical Oncology: Handbook of Cancer Diagnosis and Treatment Evaluation. Informa Healthcare, New York. Interviews Interview (2004) JAMA 292, 675. Laura van ‘t Veer, PhD: bringing tumor gene profiles into the clinic. Interview (2006) Cancer World 12, 6-13. Laura van ‘t Veer: the person behind personalised treatment. Report/Book Page 35 of 38 Laura J. van ‘t Veer – CV Dutch Cancer Society Publication (2007) ‘Biomarkers en Kanker’. Survey and practical guide for researchers, physicians and interested lay men on molecular biomarkers, including hereditary genetics, tumor and serum markers for the risk assessment, diagnosis and therapy choice of cancer (state-of-the-art, organization and recommendations for the future). (168 pages). Chair writing committee ‘Biomarkers en Kanker’, L.J. Van ‘t Veer. PATENTS ISSUED OR PENDING WO2002103320 27-12-02 Diagnosis and prognosis of breast cancer patients Co-inventor WO2004065545 15-08-04 Diagnosis and prognosis of breast cancer patients Co-inventor WO2005086891 22-09-05 Classification of breast cancer patients using a combination of clinical criteria and informative genes Co-inventor WO2006015312 09-02-06 Prognosis of breast cancer patients Co-inventor JIB-3095P 07-12-11 Biomarkers for prediction of response to PARP inhibition in Breast Cancer Co-inventor JIB-3095-PCT 07-12-12 Biomarkers for prediction of response to PARP inhibition in Breast Cancer Co-inventor OTHER CREATIVE ACTIVITIES Not applicable ABSTRACTS: 1. Van ‘t Veer, L.J.*, Dai, H.*, Van de Vijver, M.J.*, He, Y.D., Hart, A.A.M., Mao, M., Peterse, J.L., Van der Kooij, K., Marton, M.J., Witteveen, A.T., Schreiber, G.J., Kerkhoven, R.M., Roberts, C., Linsley, P.S., Bernards, R., Friend, S.H. (2002) Gene expression profiling of breast cancer predicts clinical outcome of disease. Nature 615, 530-536. * as equal first authors Abstract Breast cancer patients presenting with the same stage of disease can have markedly different treatment responses and overall outcome. Currently available predictors fail to accurately classify breast tumours according to their clinical behaviour and are unreliable with respect to determining the exact need for adjuvant therapy. Here we have used gene expression profiling with DNA microarrays on primary breast tumours of 117 young patients and applied supervised classification to identify a gene expression signature strongly predictive of a short interval to distant metastases. In addition, a signature was established that identifies tumours of BRCA1 germline mutation carriers. The “poor prognosis signature” was found to consist of genes that function in regulation of cell cycle, invasion, metastasis, and angiogenesis. Patients having tumours with the “poor prognosis signature” have an up to 28-fold increased risk to develop distant metastases within 5 years. Statistical analysis shows that the gene expression profile is an independent parameter that will outperform all currently used clinical parameters in predicting outcome of disease. Our findings allow a better selection for patients who would benefit from adjuvant therapy. 2. Van de Vijver MJ*, He YD*, Van ’t Veer LJ*, Dai H, Hart AAM, Voskuil D, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ETh, Friend SH, Bernards R. A gene expression signature as a predictor of survival in breast cancer. New England J Med 2002; 347: 1999-2009. *as equal first author Abstract A more accurate means of prognostication in breast cancer will improve the selection of patients for adjuvant systemic therapy. METHODS: Using microarray analysis to evaluate our previously established 70-gene prognosis profile, we classified a series of 295 consecutive patients with primary breast carcinomas as having a gene-expression signature associated with either a poor prognosis or a good prognosis. All patients had stage I or II breast cancer and were younger than 53 years old; 151 had lymph-node-negative disease, and 144 had lymph-node-positive disease. We evaluated the predictive power of the prognosis profile using univariable and multivariable statistical analyses. RESULTS: Among the 295 patients, 180 had a poor-prognosis signature and 115 had a good-prognosis signature, and the mean (+/-SE) overall 10-year survival rates were 54.6+/-4.4 percent and 94.5+/-2.6 percent, respectively. At 10 years, the probability of remaining free of distant metastases was 50.6+/-4.5 percent in the group with a poor-prognosis signature and 85.2+/-4.3 percent in the group with a good-prognosis signature. The estimated hazard ratio for distant metastases in the group with a poor-prognosis signature, as compared with the group with the good-prognosis signature, was 5.1 (95 percent confidence interval, 2.9 to 9.0; P<0.001). This ratio remained significant when the groups were analyzed according to lymph-node status. Multivariable Cox regression analysis showed that the prognosis profile was a strong Page 36 of 38 Laura J. van ‘t Veer – CV independent factor in predicting disease outcome. CONCLUSIONS: The gene-expression profile we studied is a more powerful predictor of the outcome of disease in young patients with breast cancer than standard systems based on clinical and histologic criteria. 3. Schmidt, M.K., Tollenaar, R.A.E.M., De Kemp, S., Broeks, A., Cornelisse, C.J., Smit, V.T.H.B.M., Peterse, J.L., Van Leeuwen, F.E., Van ‘t Veer, L.J. (2007) Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol. 25, 64-69. Abstract Purpose: Women carrying a CHEK2*1100delC germline mutation have an increased risk to develop breast cancer. This study aims to determine the proportion of CHEK2*1100delC carriers in a premenopausal breast cancer population, unselected for family history of breast cancer, and to investigate tumor characteristics and disease outcome with sufficient follow-up. Patients and Methods: We identified a retrospective cohort of 1479 patients, who received surgery for invasive breast cancer between 1970 and 1994. All patients were diagnosed before age 50. Paraffin-embedded tissue blocks were collected for DNA isolation (normal tissue), subsequent CHEK2*1100delC analysis, and tumor revision. Median follow-up was 10.1 years. Results: We detected a CHEK2*1100delC germline mutation in 54 patients (3.7%). Tumor characteristics of CHEK2*1100delC carriers did not differ significantly from those of non-carriers. CHEK2*1100delC carriers had a two-fold increased risk (Hazard Ratio 2.1 (1.0-4.3) p=0.049) to develop a second breast cancer and they had worse recurrence-free survival (HR 1.7 (1.2-2.4) p=0.006) and worse breast cancer-specific survival (HR 1.4 (1.0-2.1) p=0.072), compared to non-carriers. The poorer disease outcome of CHEK2*1100delC carriers could not be explained by the increased risk of second breast cancer. Conclusion: Our study, representative for the premenopausal breast cancer population, reveals ~4% CHEK2*1100delC carriers (irrespective of family history) with an increased risk of second breast cancer and worse long-term recurrence-free survival. Their identification at time of diagnosis and prolonged intensive follow-up should be considered to optimize clinical management. RESEARCH PROGRAM Dr. van ‘t Veer’s research focuses on Personalized Medicine, to advance that patient management based on knowledge of the genetic make-up of the tumor as well as the genetic make-up of the patient. This allows the optimal assignment of systemic therapy for those patients that are in need of such treatment and to ensure the selection of the therapy that is most effective. Dr. van ‘t Veer’s research shows that molecular diagnostics and microarray genomics technology increasingly impacts patient management. Molecular Genomics contributes to the knowledge of who is at risk for breast cancer, how external factors may influence this risk, whether breast tumors are likely to metastasize or not, and which subtype of tumors will likely respond to what therapy. The research of Dr. van ‘t Veer’s group started early in 1994, for which numerous competitive grants were obtained and where parallel research lines can be distinguished: - Molecular markers of breast cancer: Studies on the functional activity of the estrogen receptor, the detection of minimal disease, and molecular profiling of tumors for hereditary susceptibility, prognosis and therapy response prediction. The latter profiling theme is part of the national genomics initiative, Cancer Genomics and forms the basis of the International Randomized trial MINDACT (BIG03-4, EORTC1041). - Genetic risk factors for breast cancer: Studies on the contribution of DNA damage repair germline mutations to the risk of radiation-induced breast cancer, and risk assessment and gene-environment interactions in (hereditary) breast cancer. The latter is part of the recently started international consortia BCAC and EU funded COGS. - Prognostic and Predictive factors in Colorectal Cancer: To study the avoidance of overtreatment with radiotherapy in rectal cancer and to define genomic factors for the prediction of colon cancer recurrence. Dr. Van ‘t Veer is first author of a study showing that microarray genomics technology can predict which breast tumors will likely metastasize and which will not (Nature 2002, NEJM 2002). Current implementation of this finding into daily clinical practice could reduce overtreatment of adjuvant chemotherapy by up to thirty percent. This microarray test now called MammaPrint, is central to the work of the translational research network TRANSBIG (Translational Research Breast International Group). TRANSBIG is partially funded by the European Commission under the 6th Framework Program and coordinated by a combined BIG/TRANSBIG Project Management, TRANSBIG involves about 40 partners in over 20 countries. In TRANSBIG, the validity of the microarray test is being evaluated in a 6600 patient prospective clinical trial of the EORTC/BIG called MINDACT (microarray in up to 3 positive nodes disease may avoid chemotherapy). The MINDACT trial is worldwide the first large scale clinical trial implementing genomics and recently completed accrual. Dr. van ‘t Veer’s group is participating in various aspects of the translational research of this clinical trial. Dr. van ‘t Veer’s initial research at UCSF revolved around the I-SPY 1 and 2 clinical trials for breast cancer and the development of biomarkers to predict response to therapy and outcome. One aim of these trials is to develop predictors of response (pathological response at the time of surgery and long term survival) from serial MRI data and from molecular biomarkers Page 37 of 38 Laura J. van ‘t Veer – CV obtained from serial biospecimens. Ongoing analysis is aimed at identifying signatures of response in a variety of cellular processes (proliferation, angiogenesis, apoptosis, metastasis) from expression array and pathological data obtained for patients in the completed I-SPY 1 trial in which patients were given neoadjuvant taxanes and anthracyclines. Future studies will perform similar analysis in for patients undergoing the I-SPY 2 trial in which patients receive a novel pathway specific targeted therapy in addition to neoadjuvant taxanes. One goal of these studies is to obtain new biomarkers or signatures that will allow use of a patients genomic and proteomic profile to determine the most effective treatment strategy. To facilitate this work Dr. van ‘t Veer established a CLIA certified laboratory to support the I-SPY 2 trial and other UCSF based clinical trials. This laboratory will take molecular tests shown in the research environment to have value in determining therapeutic approaches or outcome and develop and validate them for clinical use. Drug Response Companion Diagnostics Testing in vitro Derived Genomic Drug Response Predictors in the I-SPY 2 trial. Work from the Gray lab (OHSU, OR) and a growing genome science literature that has demonstrated (a) that human breast cancers are (epi)genomically heterogeneous but can be organized into molecularly distinct subtypes that progress and respond to treatment differently and (b) that the microenvironments in which tumor cells reside influence their malignant progression and therapeutic responses. Dr. van ‘t Veer’s group uses a collection of extensively characterized breast cancer cell lines grown on tumor-mimetic microenvironments to model human breast cancer subtypes and their microenvironments. Dr. van ‘t Veer’s group will measure the therapeutic responses of the cell lines in different microenvironments and correlate these with the molecular features of the cell lines and microenvironments to identify molecular predictors of response, in particular, the model responses to agents in the ongoing I-SPY 2 clinical trial so that laboratory predictions can be tested quickly in a clinical setting. Dr. van ‘t Veer’s group will test preclinical therapy response signatures for their ability to predict quantitative responses of patients to the targeted therapies in I-SPY 2. Detecting the early oncogenic kinome signature of breast cancer. The transition of normal mammary epithelial cells into malignant diseased ones is mediated through a myriad of disrupted kinase signaling cascades. Detecting such molecular events represents a unique opportunity to identify –and therefore treat– breast cancer early on. In order to systematically map phosphorylation networks in clinical or laboratory settings, Dr. van ‘t Veer’s group developed a kinase-sensing microarray platform, and propose to measure the signaling activity of a defined set of kinases in breast cancer cells or tissues using this original multiplex, phosphorylation-sensing technology. This strategy will identify immediately relevant activity patterns of oncogenic kinases regulating breast tumorigenesis. Such an innovative phospho-signature profiling device will support earlier detection of breast cancer and guide new therapeutic interventions to improve patients’ outcome. Page 38 of 38
